UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: December 31, 20162017

 

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ____________to _____________

 

Commission File Number: 001-37357

 

Cellceutix CorporationINNOVATION PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Nevada

30-0565645

(State or other jurisdiction ofincorporation or organization)

(I.R.S. Empl. Ident. No.)

incorporation or organization)

 

100 CummingCummings Center, Suite 151-B

Beverly, MA 01915

(Address of principal executive offices, Zip Code)

 

(978)-921-4125

(Registrant’s telephone number, including area code)

 

(Former Name, Former Address and Former Fiscal Year if Changed Since Last Report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “smaller reporting“emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer

¨

Accelerated Filer

x

Non-Accelerated Filer

¨

Smaller reporting company

¨

(Do not check if a smaller reporting company)

Emerging growth company

¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

 

The number of shares outstanding of each of the issuer’s classes of common equity, as of January 27, 201731, 2018 is as follows:

 

Class of Securities

Shares Outstanding

Common Stock Class A, $0.0001 par value

126,408,756

145,688,782 

Common Stock Class B, $0.0001 par value

None

 

 
 
 

CELLCEUTIX CORPORATIONINNOVATION PHARMACEUTICALS INC.

FORM 10-Q

For the Quarter Ended December 31 2016, 2017

 

TABLE OF CONTENTS

 

PART I – FINANCIAL INFORMATION

 

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements (unaudited)

4

 

Condensed Balance Sheets as of December 31, 20162017 (unaudited) and June 30, 20162017 (audited)

4

 

Condensed Statements of Operations (unaudited) for the three months and six months ended December 31, 20162017 and 20152016

5

 

Condensed Statements of Cash Flows (unaudited) for the six months ended December 31, 20162017 and 20152016

6

 

Notes to Condensed Financial Statements (unaudited)

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

20

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

2931

Item 4.

Controls and Procedures

30

 

32

 

PART II – OTHER INFORMATION

 

Item 1.

Legal Proceedings

3133

Item 1A

Risk Factors

3133

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

3133

Item 3.

Defaults Upon Senior Securities

3133

Item 4.

Mine Safety Disclosures

3133

Item 5.

Other Information

3133

Item 6.

Exhibits

3234

 

SIGNATURES

3335

 

 
2
Table of Contents

 

FORWARD-LOOKING STATEMENTS

 

This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When we use the words intends,“intends,” “estimates,” “predicts,” “potential,” “continues,” “anticipates,” “plans,” “expects,” “believes,” “should,” “could,” “may,” “will” or the negative of these terms or other comparable terminology, we are identifying forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning our future drug development plans and projected timelines for the initiation and completion of preclinical and clinical trials; the potential for the results of ongoing preclinical or clinical trials; other statements regarding our future product development and regulatory strategies, including with respect to specific indications; any statements regarding our future financial performance, results of operations or sufficiency of capital resources to fund our operating requirements; any statements relating to potential out-licensing, partnership or joint venture agreements with third parties; and any other statements which are other than statements of historical fact. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by forward-looking statements. These factors include, but are not limited to, our ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially-viable drugs; our ability to effectively and timely conduct clinical trials; our ability to ultimately distribute our drug candidates; compliance with regulatory requirements; and our capital needs, as well as other factors described elsewhere in this report and our other reports filed with the Securities and Exchange Commission (the “SEC”). Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

Forward-looking statements speak only as of the date on which they are made. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in this report and our other reports filed with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business. Readers are cautioned not to put undue reliance on forward-looking statements.

 

For further information about these and other risks, uncertainties and factors, please review the disclosure included in our Annual Report on Form 10-K under “Part I, Item 1A, Risk Factors” and in this report under “Part II, Item 1A, Risk Factors.”

 

 
3
Table of Contents

 

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

CELLCEUTIX CORPORATIONINNOVATION PHARMACEUTICALS INC.

CONDENSED BALANCE SHEETS

(Rounded to nearest thousand except for per shareshares data)

 

 

December 31,

 

June 30,

 

 

December 31,

 

June 30,

 

 

2016

 

 

2016

 

 

2017

 

 

2017

 

 

(Unaudited)

 

 

 

 

(Unaudited)

 

 

 

ASSETS

ASSETS

ASSETS

Current Assets:

 

 

 

 

 

 

 

 

 

 

Cash

 

$3,859,000

 

$6,310,000

 

 

$3,181,000

 

$4,141,000

 

Prepaid expenses

 

199,000

 

272,000

 

 

94,000

 

308,000

 

Security deposits

 

78,000

 

-

 

Subscription receivable

 

 

26,000

 

 

 

26,000

 

 

 

-

 

 

 

26,000

 

Total Current Assets

 

 

4,084,000

 

 

 

6,608,000

 

 

 

3,353,000

 

 

 

4,475,000

 

 

 

 

 

 

Other Assets:

 

 

 

 

 

 

 

 

 

 

Patent costs - net

 

4,181,000

 

4,311,000

 

Property, plant and equipment -net

 

139,000

 

90,000

 

Deferred offering costs

 

310,000

 

358,000

 

Patents - net

 

4,100,000

 

4,212,000

 

Equipment - net

 

102,000

 

120,000

 

Deferred offering costs - net

 

183,000

 

227,000

 

Security deposits

 

 

78,000

 

 

 

78,000

 

 

 

-

 

 

 

78,000

 

Total Other Assets

 

 

4,708,000

 

 

 

4,837,000

 

 

 

4,385,000

 

 

 

4,637,000

 

 

 

 

 

 

Total Assets

 

$8,792,000

 

 

$11,445,000

 

 

$7,738,000

 

 

$9,112,000

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

LIABILITIES AND STOCKHOLDERS' DEFICIENCY

Current Liabilities:

 

 

 

 

 

 

 

 

 

 

Accounts payable - (including related party payables of approx. $1,504,000 and $1,502,000, respectively)

 

$3,223,000

 

$3,528,000

 

Accrued expenses - (including related party accruals of approx. $139,000 and $72,000, respectively)

 

549,000

 

97,000

 

Accrued salaries and payroll taxes -(including related party accrued salaries of approx. $2,777,000 and $2,777,000, respectively)

 

2,862,000

 

2,834,000

 

Note payable - related party

 

 

2,022,000

 

 

 

2,022,000

 

Accounts payable - (including related party payables of approximately $1,486,000 and 1,506,000, respectively)

 

$4,850,000

 

$4,699,000

 

Accrued expenses - (including related party accruals of approximately $37,000 and $38,000, respectively)

 

548,000

 

711,000

 

Accrued salaries and payroll taxes - (including related party accrued salaries of approximately $2,953,000 and $2,953,000, respectively)

 

3,197,000

 

3,144,000

 

Convertible note payable - related party

 

 

2,022,000

 

 

 

2,022,000

 

Total Current Liabilities

 

 

8,656,000

 

 

 

8,481,000

 

 

 

10,617,000

 

 

 

10,576,000

 

 

 

 

 

 

Total Liabilities

 

 

8,656,000

 

 

 

8,481,000

 

 

 

10,617,000

 

 

 

10,576,000

 

 

 

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 8)

 

 

 

 

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' Equity

 

 

 

 

 

Preferred stock, $0.001 par value, 500,000 designated shares, no shares issued and outstanding

 

-

 

-

 

Common Stock - Class A, $.0001 par value, 300,000,000 shares authorized, 126,008,756 and 123,589,536 issued and outstanding as of December 31, 2016 and June 30, 2016, respectively

 

13,000

 

12,000

 

Common Stock - Class B, (10 votes per share); $.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding as of December 31, 2016 and June 30, 2016, respectively

 

-

 

-

 

Stockholders’ Deficiency

 

 

 

 

 

Preferred stock, $0.001 par value, 10,000,000 designated shares, no shares issued and outstanding

 

-

 

-

 

Common Stock - Class A, $0.0001 par value, 300,000,000 shares authorized, 145,555,966 and 135,536,501 issued as of December 31, 2017 and June 30, 2017, respectively, 144,988,782 and 135,274,421 outstanding as of December 31, 2017 and June 30, 2017, respectively

 

15,000

 

14,000

 

Common Stock - Class B, (10 votes per share); $0.0001 par value, 100,000,000 shares authorized, no shares issued and outstanding as of December 31, 2017 and June 30, 2017, respectively

 

-

 

-

 

Additional paid-in capital

 

60,526,000

 

56,969,000

 

 

76,128,000

 

68,295,000

 

Accumulated deficit

 

 

(60,403,000)

 

 

(54,017,000)

 

(78,605,000)

 

(69,553,000)

Total Stockholders' Equity

 

 

136,000

 

 

 

2,964,000

 

 

 

 

 

 

Total Liabilities and Stockholders' Equity

 

$8,792,000

 

 

$11,445,000

 

Treasury Stock, at cost (567,184 shares and 262,080 shares as of December 31, 2017 and June 30, 2017, respectively)

 

 

(417,000)

 

 

(220,000)

Total Stockholders’ Deficiency

 

 

(2,879,000)

 

 

(1,464,000)

Total Liabilities and Stockholders’ Deficiency

 

$7,738,000

 

 

$9,112,000

 

 

The accompanying notes are an integral part of these condensed financial statements

 

 
4
Table of Contents

 

CELLCEUTIX CORPORATIONINNOVATION PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF OPERATIONS

FOR THE THREE MONTHS AND SIX MONTHS ENDED DECEMBER 31 2016, 2017 AND 20152016

(Unaudited)

(Rounded to nearest thousand except for shares and per share data)

 

 

For the Three Months Ended

 

For the Six Months Ended

 

 

For the Three Months

Ended

 

For the Six Months

Ended

 

 

December 31,

 

December 31,

 

 

December 31,

 

December 31,

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$-

 

 

$-

 

 

$ -

 

 

$ -

 

 

$-

 

 

$-

 

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

2,683,000

 

2,130,000

 

4,960,000

 

3,961,000

 

 

3,963,000

 

2,683,000

 

7,768,000

 

4,960,000

 

General and administrative expenses

 

344,000

 

352,000

 

706,000

 

691,000

 

 

297,000

 

344,000

 

594,000

 

706,000

 

Officers' payroll and payroll tax expenses

 

130,000

 

130,000

 

260,000

 

260,000

 

 

130,000

 

130,000

 

260,000

 

260,000

 

Professional fees

 

 

152,000

 

 

 

662,000

 

 

 

361,000

 

 

 

889,000

 

 

 

78,000

 

 

 

152,000

 

 

 

330,000

 

 

 

361,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total operating expenses

 

 

3,309,000

 

 

 

3,274,000

 

 

 

6,287,000

 

 

 

5,801,000

 

 

 

4,468,000

 

 

 

3,309,000

 

 

 

8,952,000

 

 

 

6,287,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(3,309,000)

 

 

(3,274,000)

 

 

(6,287,000)

 

 

(5,801,000)

 

 

(4,468,000)

 

 

(3,309,000)

 

 

(8,952,000)

 

 

(6,287,000)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expenses)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

1,000

 

1,000

 

2,000

 

2,000

 

 

-

 

1,000

 

1,000

 

2,000

 

Interest expense

 

(50,000)

 

(50,000)

 

(101,000)

 

(101,000)

 

 

(50,000)

 

 

(50,000)

 

 

(101,000)

 

 

(101,000)

Total other income (expenses)

 

 

(49,000)

 

 

(49,000)

 

 

(99,000)

 

 

(99,000)

Total other income - net

 

 

(50,000)

 

 

(49,000)

 

 

(100,000)

 

 

(99,000)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss before provision for income taxes

 

(3,358,000)

 

(3,323,000)

 

(6,386,000)

 

(5,900,000)

 

(4,518,000)

 

(3,358,000)

 

(9,052,000)

 

(6,386,000)

Provision for income taxes

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(3,358,000)

 

$(3,323,000)

 

$

 (6,386,000

)

 

$(5,900,000)

 

$(4,518,000)

 

$(3,358,000)

 

$(9,052,000)

 

$(6,386,000)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per share attributable to common stockholders

 

$(0.03)

 

$(0.03)

 

$

 (0.05

)

 

$(0.05)

Basic and diluted loss per share

 

$(0.03)

 

$(0.03)

 

$(0.07)

 

$(0.05)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding

 

 

125,275,060

 

 

 

118,673,362

 

 

 

124,782,071

 

 

 

118,406,893

 

 

 

140,749,557

 

 

 

125,275,060

 

 

 

138,960,684

 

 

 

124,782,071

 

 

The accompanying notes are an integral part of these condensed financial statements.


 
5
Table of Contents

 

CELLCEUTIX CORPORATIONINNOVATION PHARMACEUTICALS INC.

CONDENSED STATEMENTS OF CASH FLOW

FOR THE SIX MONTHS ENDED DECEMBER 31, 20162017 AND 20152016

(Unaudited)

(Rounded to nearest thousand)

 

 

2016

 

 

2015

 

 

2017

 

 

2016

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Net loss

 

$(6,386,000)

 

$(5,900,000)

 

$(9,052,000)

 

$(6,386,000)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

 

 

Common stock and stock options issued as payment for services

 

690,000

 

530,000

 

Common stock and stock options issued as payment for compensation, services rendered and financing costs

 

1,400,000

 

690,000

 

Amortization of patent costs

 

183,000

 

204,000

 

 

192,000

 

183,000

 

Depreciation of equipment

 

15,000

 

5,000

 

 

18,000

 

15,000

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

Prepaid expenses and other current assets

 

73,000

 

172,000

 

Prepaid expenses and security deposits

 

214,000

 

73,000

 

Accounts payable

 

(305,000)

 

259,000

 

 

151,000

 

(305,000)

Accrued expenses

 

452,000

 

93,000

 

 

(163,000)

 

452,000

 

Accrued officers' salaries and payroll taxes

 

 

28,000

 

 

 

(3,000)

 

 

53,000

 

 

 

28,000

 

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

 

(5,250,000)

 

 

(4,640,000)

 

 

(7,187,000)

 

 

(5,250,000)

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Additions to property, plant and equipment

 

(64,000)

 

-

 

 

-

 

(64,000)

Patent costs

 

 

(53,000)

 

 

(217,000)

 

 

(80,000)

 

 

(53,000)

 

 

 

 

 

 

 

 

 

 

Net cash used in investing activities

 

 

(117,000)

 

 

(217,000)

 

 

(80,000)

 

 

(117,000)

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

Sales of common stock

 

2,916,000

 

2,618,000

 

Exercise of stock options and warrants

 

 

-

 

 

 

12,000

 

Sales of common stock, net of offering costs

 

6,478,000

 

2,916,000

 

Purchase of treasury stock

 

 

(171,000)

 

 

-

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by financing activities

 

 

2,916,000

 

 

 

2,630,000

 

 

 

6,307,000

 

 

 

2,916,000

 

 

 

 

 

 

 

 

 

 

 

NET DECREASE IN CASH

 

(2,451,000)

 

(2,227,000)

 

(960,000)

 

(2,451,000)

 

 

 

 

 

 

 

 

 

 

CASH, BEGINNING OF PERIOD

 

 

6,310,000

 

 

 

8,410,000

 

 

 

4,141,000

 

 

 

6,310,000

 

 

 

 

 

 

 

 

 

 

 

CASH, END OF PERIOD

 

$3,859,000

 

 

$6,183,000

 

 

$3,181,000

 

 

$3,859,000

 

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION

 

 

 

 

 

 

 

 

 

 

Cash paid for interest

 

$29,000

 

 

$29,000

 

 

$96,000

 

 

$29,000

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURE OF NON-CASH FLOW

 

 

 

 

 

INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

Commitment shares issued as deferred offering costs

 

$215,000

 

 

$-

 

Reversal of subscription receivable to treasury stock

 

$26,000

 

 

$-

 

 

The accompanying notes are an integral part of these condensed financial statements.


 
6
Table of Contents

 

CELLCEUTIX CORPORATIONINNOVATION PHARMACEUTICALS INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

DECEMBER 31 2016, 2017

(Unaudited)

 

Note 1. Basis of Presentation and Nature of Operations

 

Unaudited Interim Financial Information

 

The accompanying unaudited condensed financial statements of Cellceutix CorporationInnovation Pharmaceuticals Inc. have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission, or the SEC, including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements for the year ended June 30, 2016,2017, included in our Annual Report on Form 10-K for the year ended June 30, 2016.2017.

 

In the opinion of the management of the Company,Innovation Pharmaceuticals Inc., all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three monththree-month and six monthsix-month periods have been made. Results for the interim periodperiods presented are not necessarily indicative of the results that might be expected for the entire fiscal year. When used in these notes, the terms "Company"“Company”, "we"“we”, "us"“us” or "our"“our” mean Cellceutix Corporation. Innovation Pharmaceuticals Inc.

 

Basis of Presentation and Name Change

 

Cellceutix CorporationInnovation Pharmaceuticals Inc. (the “Company”) was incorporated as Econoshare, Inc. on August 1, 2005, in the State of Nevada. On December 6, 2007,Effective June 5, 2017, the Company acquired Cellceutix Pharma, Inc., a privately owned corporation formed under the lawsamended its Articles of the State of Delaware on June 20, 2007. Following the acquisition, the CompanyIncorporation and changed its name from Cellceutix Corporation to Cellceutix Corporation.Innovation Pharmaceuticals Inc. In accordance with Section 92A.180 of the Nevada Revised Statutes, stockholder approval of the name change was not required.

 

The Company is a clinical stage biopharmaceutical company and has no customers, products or revenues to date. The Company’s Common Stockcommon stock is quoted on OTCQB, symbol “CTIX”“IPIX”.

 

Nature of Operations -Overview

 

We are in the business of developing innovative small molecule therapies to treat diseases with significant medical need, particularly in the areas of inflammatory diseases, cancer, antibioticsdermatology and inflammatory disease.anti-infectives. Our strategy is to use our business and scientific expertise to maximize the value of our pipeline. We will do this by focusing initially on our lead compounds, Brilacidin, Kevetrin and Prurisol and advancing them as quickly as possible along the regulatory pathway. We will develop the highest quality data and broadest intellectual property to support our compounds.

 

We currently own all development and marketing rights to our products. In order to successfully develop and market our products, we may have to partner with other companies. Prospective partners may require that we grant them significant development and/or commercialization rights in return for agreeing to share the risk of development and/or commercialization.

 

Note 2. Going Concern and Liquidity

As of June 30, 2017, the Company adopted Accounting Standards Codification 205-40. This guidance amended the existing requirements for disclosing information about an entity’s ability to continue as a going concern and explicitly requires management to assess an entity’s ability to continue as a going concern and to provide related disclosure in certain circumstances. This guidance was effective for annual reporting periods ending after December 15, 2016, and for annual and interim reporting periods thereafter. The following information reflects the results of management’s assessment, plans and conclusion of the Company’s ability to continue as a going concern.

7
Table of Contents

We have incurred recurring losses since inception and expect to continue to incur losses as a result of costs and expenses related to our research and continued development of our compounds and our corporate general and administrative expenses. As of December 31, 2017, the Company has an accumulated deficit of $79 million, representative of recurring losses since inception. The Company is a development stage pharmaceutical company that has no sales as it does not have any products in the market and will continue to not have any revenues until it begins to market its products after it has obtained the necessary Federal Drug Administration (the “FDA”) approval. As a result, the Company expects to continue to incur losses.

 

At December 31, 2016, we2017, the Company’s cash amounted to $3.2 million and current liabilities amounted to $10.6 million, of which $6.5 million were payables to related parties with no immediate payment terms (See Note 8- Related Party Transactions in the Notes to Condensed Financial Statements section below). The Company had $3.9 million in cash. We have expended substantial funds on theits clinical trials and expects to continue our spending on research and development of our product candidates.expenditures. The Company’s net cash used in operating activities for the six months ended December 31, 2017 was approximately $7.2 million, and current projections indicate that the Company will have continued negative cash flows from operating activities for the foreseeable future. Our net losses incurred for the six months ended December 31, 20162017 and 2015,2016, amounted to $6.4$9.1 million and $5.9$6.4 million, respectively, and we had a working capital deficit ofdeficits was approximately $4.6$7.3 million and $1.9$6.1 million respectively at December 31, 20162017 and June 30, 2016.2017, respectively.

 

On March 30, 2015,Accordingly, the Company entered intoCompany’s planned operations, including total budgeted expenditures of approximately $12.2 million for the next twelve months, raise doubt about its ability to continue as a going concern. The Company’s plans to alleviate the doubt of its ability to continue as a going concern primarily include controlling the timing and spending on its research and development programs and raising additional funds through equity financings from its common stock purchase agreement with Aspire Capital Fund, LLC, an Illinois limited liability company ("(“Aspire Capital"Capital”) which provides. The Company may consider other plans to fund operations including: (1) raising additional capital through debt financings or from other sources; (2) additional funding through new relationships to help fund future clinical trial costs (i.e. licensing and partnerships); (3) reducing spending on one or more research and development programs by discontinuing development; and/or (4) restructuring operations to change its overhead structure. The Company may issue securities, including shares of common stock, shares of preferred stock and stock purchase contracts through private placement transactions or registered public offerings, pursuant to its registration statement on Form S-3 filed with the SEC on September 11, 2017. The Company’s future liquidity needs, and ability to address those needs, will largely be determined by the success of its product candidates and key development and regulatory events and its decisions in the future.

The Company believes that upon the termsactions discussed above are probable of occurring and subject toalleviating the conditionssubstantial doubt raised by our historical operating results and limitations set forth therein,satisfying our estimated liquidity needs twelve months from the issuance of the accompanying financial statements.

On September 6, 2017, the Company entered into a new $30 million common stock purchase agreement with Aspire Capital is committed(the “2017 Agreement”) to purchase up to an aggregate of $30.0replace the prior 2015 $30 million of the Company's common stock overpurchase agreement with Aspire Capital (the “2015 Agreement”). During the 36-month termperiod from July 1, 2017 to September 5, 2017, the Company generated proceeds of approximately $2.1 million under the Purchase Agreement.2015 Agreement from the sale of approximately 2.6 million shares of its common stock. During the period from September 6, 2017 to December 31, 2017, the Company generated proceeds of approximately $4.4 million under the 2017 Agreement from the sale of approximately 6.6 million shares of its common stock. As of December 31, 2016,2017, the available balance under the 2017 Agreement is approximately $19 million under this stock purchase agreement.

7
Table of Contents
$25.6 million.

 

The Company plans to incur expenses of approximately $19 million over the next twelve months, including approximately $15 million for clinical trials. The Company has limited experience with pharmaceutical drug development. As such, the budget estimate may not be accurate. In addition, the actual work to be performed is not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become necessary or change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget and on our projected timeline of drug development.

Management believes that the amounts available from Aspire Capital and under the Company’s effective shelf registration statement will be sufficient to fund the Company’s operations for the next 12 months.

If we are unable to generate enough working capital from our current financing agreement with Aspire Capital when needed or secure additional sources of funding, it may be necessary to significantly reduce our current rate of spending through reductions in staff and delaying, scaling back or stopping certain research and development programs, including more costly Phase 2 and Phase 3 clinical trials on our wholly-owned development programs as these programs progress into later stage development. Insufficient liquidity may also require us to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to us and our stockholders than we would otherwise choose in order to obtain up-front license fees needed to fund operations. These events could prevent us from successfully executing our operating plan.

Note 3. Significant Accounting Policies and Recent Accounting Pronouncements

 

Reclassifications

Certain prior year amounts have been reclassified to conform to current period presentation. Such reclassifications were limited to the Condensed Balance Sheets and did not impact the Condensed Statement of Operations and Condensed Statement of Cash Flows.

Use of Estimates

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Significant items subject to such estimates and assumptions include contract research accruals, recoverability of long-lived assets, measurement of stock-based compensation, and the periods of performance under collaborative research and development agreements. The Company bases its estimates on historical experience and various other assumptions that management believes to be reasonable under the circumstances. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates.

 

8
Table of Contents

Basic Earnings (Loss) perNet Loss Per Share

 

Basic and diluted earnings (loss)loss per share areis computed based on the weighted-average common shares and common share equivalents outstanding during the period. Common share equivalents consist of stock options, warrants and convertible notes payable.payable underlying shares and unvested restricted stock. Common share equivalents of 46.7 million and 45.1 million shares and 44.0 million sharesof common stock were excluded from the computation of diluted earnings (loss)loss per share for the three months and six months ended December 31, 2017 and 2016, respectively, because we incurred net losses for the six months ended December 31, 2017 and 2016, and 2015, respectively, because theirthe effect is anti-dilutive.of including these potential common shares in the net loss per share calculations would be anti-dilutive and are therefore not included in the calculations.

 

Treasury Stock

The Company accounts for treasury stock using the cost method. There were 567,184 shares and 262,080 shares of treasury stock outstanding, purchased at a total cumulative cost of $417,000 and $220,000 at December 31, 2017 and June 30, 2017, respectively (see Note 10).

Treasury stock, representing shares of the Company’s common stock that have been acquired for payroll tax withholding on vested stock grants, is recorded at its acquisition cost and these shares are not considered outstanding.

Accounting for Stock Based Compensation

 

The stock-based compensation expense incurred by Cellceutixthe Company for employees and directors in connection with its stock option plan is based on the employee model of ASC 718, and the fair market value of the options is measured at the grant date. Under ASC 718, an employee is defined as “An individual over whom the grantor of a share-based compensation award exercises or has the right to exercise sufficient control to establish an employer-employee relationship based on common law as illustrated in case law and currently under U.S. tax regulations”. Our consultants do not meet the employer-employee relationship as defined by the IRS and therefore are accounted for under ASC 505-50.

8
Table of Contents

 

ASC 505-50-30-11 further provides that an issuer shall measure the fair value of the equity instruments in these transactions using the stock price and other measurement assumptions as of the earlier of the following dates, referred to as the measurement date:

 

 

i.

The date at which a commitment for performance by the counterparty to earn the equity instruments is reached (a performance commitment); and

 

ii.

The date at which the counterparty’s performance is complete.

 

We have elected to use the Black-Scholes-Merton pricing model to determine the fair value of stock options on the dates of grant. Restricted stock is measured based on the fair market values of the underlying stock on the dates of grant. We recognize stock-based compensation using the straight-line vesting method over the requisite service period of the equity awards.

 

The components of stock basedstock-based compensation related to stock options and stock awardsexpense included in the Company’s StatementCondensed Statements of Operations for the three months and six months ended December 31, 20162017 and 20152016 are as follows (rounded to nearest thousand):

 

 

Three Months Ended

 

Six Months Ended

 

 

Three months ended

December 31

 

Six months ended

December 31

 

 

December 31,

 

December 31,

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

General and administrative expenses

 

 

 

 

 

 

 

 

 

Professional fees

 

$-

 

$432,000

 

$-

 

$432,000

 

 

 

 

 

 

 

 

 

 

 

2017

 

 

2016

 

 

2017

 

 

2016

 

Research and development expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Professional fees

 

$8,000

 

$-

 

$50,000

 

$78,000

 

 

$-

 

$8,000

 

$-

 

$50,000

 

Employees’ bonus

 

50,000

 

-

 

62,000

 

-

 

 

42,000

 

50,000

 

74,000

 

62,000

 

Officers’ bonus

 

 

289,000

 

 

 

-

 

 

 

578,000

 

 

 

20,000

 

 

 

989,000

 

 

 

289,000

 

 

 

1,326,000

 

 

 

578,000

 

 

 

 

 

 

 

 

 

 

 

Total share-based compensation expense

 

$347,000

 

 

$432,000

 

 

$690,000

 

 

$530,000

 

Total stock-based compensation expense

 

$1,031,000

 

 

$347,000

 

 

$1,400,000

 

 

$690,000

 

 

Recent Accounting Pronouncements

Standards Issued Not Yet Adopted

In August 2014, the FASB issued ASU 2014-15, “Presentation of Financial Statements—Going Concern—Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 requires management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. ASU 2014-15 is effective for annual periods, and interim periods within those annual periods, starting after December 15, 2016; the Company’s first quarter of fiscal 2018. Management believes that the adoption of this guidance will not have a material impact on our financial statements.

In May 2014, the FASB issued authoritative guidance that defines how companies should report revenues from contracts with customers. The standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It provides companies with a single comprehensive five-step principles based model to use in accounting for revenue and supersedes current revenue recognition requirements, including most industry-specific and transaction-specific revenue guidance. In August 2015, the FASB deferred the effective date of the new revenue standard by one year. As a result, the new standard would not be effective for the Company until fiscal year 2019. In addition, the FASB is allowing companies to early adopt this guidance for non-public entities beginning in fiscal year 2017. The guidance permits an entity to apply the standard retrospectively to all prior periods presented, with certain practical expedients, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company will apply this new guidance when it becomes effective and has not yet selected a transition method. Management believes that the adoption of this guidance will not have a material impact on our financial statements.

 
9
Table of Contents

 

In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842). The guidance requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. For finance leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; interest on the lease liability will be recognized separately from amortization of the right-of-use asset in the statement of comprehensive income; and repayments of the principal portion of the lease liability will be classified within financing activities and payments of interest on the lease liability and variable lease payments within operating activities in the statement of cash flows. For operating leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; a single lease cost will be recognized, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis; and all cash payments will be classified within operating activities in the statement of cash flows. Under Topic 842 the accounting applied by a lessor is largely unchanged from that applied under previous GAAP. The amendments in Topic 842 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Management has been continuously assessing the impact of this guidance.Recent Adopted Accounting Pronouncements

 

Stock Compensation -In March 2016, the FASB issued ASU 2016-09, Compensation-Stock Compensation (“ASU 2016-09”). Under ASU 2016-09, entities– Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which will be required to recognizesimplify the income tax effects of awards in the income statement when the awards vest or are settled. The guidance on employers’consequences, accounting for an employee’s useforfeitures and classification on the Statement of Cash Flows (i) excess tax benefits be classified as cash inflows provided by operating activities, and (ii) cash paid to taxing authorities arising from the withholding of shares to satisfy the employer’s statutory income tax withholding obligation and for forfeitures is also changing. For public business entities, ASU 2016-09from employees be classified as cash outflows used in financing activities. This standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016, with early adoption permitted. This new pronouncement was adopted on July 1, 2016 and interim periods within those years. Early adoption is permitted, but all of the guidance must be adopted in the same period. Management believes that the adoption of this guidance willdid not have a material impacteffect on ourthe Company’s financial statements.

Standards Issued and Adoptedposition or results of operations, but had an effect of the classification of cash paid to taxing authorities arising from the withholding of shares from employees (treasury stock), classified as cash outflows used in financing activities.

 

In June 2014, the FASB issued ASU 2014-12, Compensation - “Compensation—Stock Compensation. The amendments in this ASU apply to reporting entities that grant their employees share-based payments in which the terms of the award provide that a performance target can be achieved after the requisite service period. This ASU is the final version of Proposed ASU EITF-13D--Compensation--StockEITF-13D, “Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period, which has been deleted. The amendments require that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. A reporting entity should apply existing guidance in Topic 718 as it relates to awards with performance conditions that affect vesting to account for such awards. As such, the performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. As indicated in the definition of vest, the stated vesting period (which includes the period in which the performance target could be achieved) may differ from the requisite service period. The amendments in this ASU are effective for annual periods and interim periods within those annual periods beginning after December 15, 2015, and early adoption is permitted. Management has adopted2015. The implementation of this guidance and itstandard did not have a material impact on ourthe Company’s accompanying condensed financial statements.


Recently Issued Accounting Guidance

In May 2014, the FASB issued authoritative guidance that defines how companies should report revenues from contracts with customers. The standard requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It provides companies with a five-step, principles-based model to use in accounting for revenue and supersedes current revenue recognition requirements, including most industry-specific and transaction-specific revenue guidance. In August 2015, the FASB deferred the effective date of the new revenue standard by one year. As a result, the new standard would not be effective for the Company until 2019. In addition, the FASB is allowing companies to early adopt this guidance for non-public entities beginning in fiscal year 2017. The guidance permits an entity to apply the standard retrospectively to all prior periods presented, with certain practical expedients, or apply the requirements in the year of adoption, through a cumulative adjustment. The Company will apply this new guidance when it becomes effective and has not yet selected a transition method. The Company, due to not having any revenue currently and in the foreseeable future, has concluded that the impact of the adoption of this accounting standard on its financial statements will not be material.

In February 2016, FASB issued ASU No. 2016-02, “Leases (Topic 842)”. The guidance requires that a lessee recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right of use asset representing its right to use the underlying asset for the lease term. The guidance requires the following for finance leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; interest on the lease liability will be recognized separately from amortization of the right-of-use asset in the statement of comprehensive income; and repayments of the principal portion of the lease liability will be classified within financing activities and payments of interest on the lease liability and variable lease payments within operating activities in the statement of cash flows. The guidance requires the following for operating leases: the right-of-use asset and a lease liability will be initially measured at the present value of the lease payments, in the statement of financial position; a single lease cost will be recognized, calculated so that the cost of the lease is allocated over the lease term on a generally straight-line basis; and all cash payments will be classified within operating activities in the statement of cash flows. Under Topic 842 the accounting applied by a lessor is largely unchanged from that applied under previous U.S. GAAP. The amendments in Topic 842 are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Management has determined that based on current accounting and lease contract information the adoption of ASU No. 2016-02 is not expected to have a significant impact on the Company’s financial position, results of operations and disclosures. However, management is continually evaluating the future impact of ASU No. 2016-02 based on changes in the Company’s financial statements through the period of adoption.

 
10
Table of Contents

 

Intangibles, Goodwill and Other —In January 2017, the FASB issued ASU No. 2017-04, “Intangibles – Goodwill and Other (Topic 350) – Simplifying the Test for Goodwill Impairment” (“ASU No. 2017-04”). To simplify the subsequent measurement of goodwill, ASU No. 2017-04 eliminates Step 2 from the goodwill impairment test. In computing the implied fair value of goodwill under Step 2, an entity had to perform procedures to determine the fair value at the impairment testing date of its assets and liabilities following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, ASU No. 2017-04 requires an entity to perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. ASU No. 2017-04 also eliminates the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. Therefore, the same impairment assessment applies to all reporting units. An entity is required to disclose the amount of goodwill allocated to each reporting unit with a zero or negative carrying amount of net assets. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. ASU No. 2017-04 is effective for fiscal years beginning after December 15, 2019. The Company will adopt ASU No. 2017-04 commencing in the first quarter of fiscal 2021. The Company does not believe this standard will have a material impact on its financial statements or the related footnote disclosures.

Statement of Cash Flows — In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force)” (“ASU No. 2016-15”). ASU No. 2016-15 clarifies how certain cash receipts and payments should be presented in the statement of cash flows. ASU No. 2016-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company will adopt ASU No. 2016-15 commencing in the first quarter of fiscal 2019. The Company does not believe this standard will have a material impact on its financial statements or the related footnote disclosures.

Note 4. Patents, net

 

Patents, net consisted of the following (rounded to nearest thousand):

 

 

Useful life

(years)

 

December 31,
2016

 

 

June 30,

2016

 

 

Useful life

(years)

 

 

December 31,

2017

 

 

June 30,

2017

 

Purchased Patent Rights – Brilacidin, and related compounds

 

14

 

$4,082,000

 

$4,082,000

 

 

14

 

$4,082,000

 

$4,082,000

 

Purchased Patent Rights – Anti-microbial – surfactants and related compounds

 

12

 

144,000

 

144,000

 

 

12

 

144,000

 

144,000

 

Patents – Kevetrin and related compounds

 

17

 

 

1,088,000

 

 

 

1,035,000

 

 

17

 

 

1,388,000

 

 

 

1,308,000

 

 

 

 

5,314,000

 

 

5,261,000

 

 

 

 

5,614,000

 

5,534,000

 

Less: Accumulated amortization for Brilacidin, Anti-microbial- surfactants and related compounds

 

 

 

(1,007,000)

 

(855,000)

 

 

 

(1,310,000)

 

(1,158,000)

Accumulated amortization for Patents – Kevetrin and related compounds

 

 

 

 

(126,000)

 

 

(95,000)

Accumulated amortization for Patents –Kevetrin and related compounds

 

 

 

 

(204,000)

 

 

(164,000)

 

 

 

 

 

 

 

 

 

 

$4,100,000

 

 

$4,212,000

 

 

 

 

$4,181,000

 

 

$4,311,000

 

 

The patents are amortized on a straight-line basis over the estimated remaining useful lives of the assets, determined to be 12-17 years from the date of acquisition.

 

Amortization expense was approximately $92,000$96,000 and $107,000,$92,000, for the three months ended December 31, 20162017 and 2015,2016, respectively and was approximately $183,000,$192,000, and $204,000$183,000 for the six months ended December 31, 20162017 and 2015,2016, respectively.

 

As
11
Table of Contents

At December 31, 2016,2017, the future amortization period for all patents was approximately 97.68 years to 1616.75 years. Future estimated annual amortization expenses are approximately $181,000$191,000 for 2017, $364,000the year ending June 30, 2018, $382,000 for each year from 20182019 to 2025, $354,000$372,000 for the year ending June 30, 2026, $352,000$370,000 for the year ending June 30, 2027, $114,000$132,000 for the year ending June 30, 2028, $61,000$78,000 for the years ending June 30, 2029 tothrough the years ended 2032, $24,000$37,000 for the year ending June 30, 2033, and $1,000$11,000 for the year ending June 30, 2034.2034 and $1,000 for the year ending June 30, 2035.

 

Note 5. Accounts Payable

Accounts payable consisted of the following (rounded to nearest thousand):

 

 

December 31,

2016

 

 

June 30,

2016

 

Accounts payable

 

$1,719,000

 

 

$2,026,000

 

Accounts payable (Note 9) – related parties

 

 

1,504,000

 

 

 

1,502,000

 

 

 

 

 

 

 

 

 

 

Total

 

$3,223,000

 

 

$3,528,000

 

During the second quarter of fiscal year 2017, the Company realized that it had improperly estimated that it owed research and development related expenses resulting from invoices under a specific research vendor contract for upfront start-up fees, amounting to $593,000. Changes in the estimated research and development expenses are accounted for in the current period. As a result, in the second quarter of fiscal 2017, the Company recorded $593,000 into income relating to the reversal of this accounts payable that was recorded as of June 30, 2016. The Company believes that the amounts recorded were not material to the Company's consolidated results of operations or consolidated financial position.

11
Table of Contents

6. Accrued Expenses

 

Accrued expenses consisted of the following (rounded to nearest thousand):

 

 

December 31,

2016

 

 

June 30,

2016

 

 

December 31,

2017

 

 

June 30,

2017

 

Accrued research and development consulting fees

 

$411,000

 

$25,000

 

 

$511,000

 

$673,000

 

Accrued rent (Note 9) – related party

 

26,000

 

32,000

 

Accrued interest – (Note 10) related party

 

 

112,000

 

 

 

40,000

 

 

 

 

 

 

 

Accrued rent (Note 8) – related parties

 

15,000

 

21,000

 

Accrued interest – (Note 9) related parties

 

 

22,000

 

 

 

17,000

 

Total

 

$549,000

 

 

$97,000

 

 

$548,000

 

 

$711,000

 

 

7.Note 6. Accrued Salaries and Payroll Taxes – Related Parties Andand Other

 

Accrued salaries and payroll taxes consisted of the following (rounded to nearest thousand):

 

 

 

December 31,

2016

 

 

June 30,

2016

 

Accrued salaries – related parties

 

$2,647,000

 

 

$2,647,000

 

Accrued payroll taxes – related parties

 

 

130,000

 

 

 

130,000

 

Withholding tax

 

 

85,000

 

 

 

57,000

 

 

 

 

 

 

 

 

 

 

Total

 

$2,862,000

 

 

$2,834,000

 

 

 

December 31,

2017

 

 

June 30,

2017

 

Accrued salaries - related parties

 

$2,823,000

 

 

$2,823,000

 

Accrued payroll taxes - related parties

 

 

130,000

 

 

 

130,000

 

Accrued employee bonuses

 

 

-

 

 

 

86,000

 

Withholding tax - payroll

 

 

244,000

 

 

 

105,000

 

Total

 

$3,197,000

 

 

$3,144,000

 

 

8.Note 7. Commitments and Contingencies

 

Lease Commitments

 

Operating Leases – Rental Property

 

The Company signed a lease extension agreement with Cummings Properties which began on October 1, 2013. The lease is for a term of five years ending on September 30, 2018, and requires monthly payments of approximately $18,000. Innovative Medical Research Inc., a company owned by Leo Ehrlich and Dr. Krishna Menon, officers of the Company, havehas co-signed the lease and subleases 200 square feet of space previously used by the Company and paypays the Company $900 per month.

 

As of December 31, 2016,2017, future minimum lease payments to Cummings Properties required under the non-cancelable operating lease are as follows (rounded to nearest thousand):

 

Year ending June 30,

 

 

 

 

 

 

2017

 

109,000

 

2018

 

217,000

 

 

$109,000

 

2019

 

 

54,000

 

 

 

54,000

 

 

 

 

Total minimum payments

 

$380,000

 

 

$163,000

 

 

Rent expense, net of lease income, under this operating lease agreement was approximately $51,000$52,000 and $50,000,$51,000 for the three months ended December 31, 20162017 and 2015,2016, respectively and was approximately $102,000$104,000 and $101,000$102,000 for the six months ended December 31, 2017 and 2016, respectively. Before September 2013, the Company paid rent to Kard Scientific for share of office space and 2015, respectively.details are shown at Note 8 - Related Party Transactions below.

12
Table of Contents

Operating Leases - Equipment

We lease equipment under a non-cancelable operating lease that expires in April, 2018. The future minimum rental commitment for our operating lease for the next twelve months is $3,000, as of December 31, 2017 and was disclosed under the caption Prepaid expenses in the accompanying balance sheets.

 

Contractual Commitments

 

The Company has nototal contractual minimum commitments of approximately $2.7 million to contract research organizations as of December 31, 2016. Services2017. Expenses are billed to Cellceutixrecognized when services are performed by the vendors.

12
Table of Contents
contract research organizations.

 

9.Note 8. Related Party Transactions

 

Office Lease

 

Dr. Menon, one of the Company’s principal shareholders,shareholder, President of Research, and Director, also serves as the Chief Operating Officer and Director of Kard Scientific (“KARD”). On December 7, 2007, the Company began renting office space from KARD, on a month to month basis for $900 per month. This continued through August 2013 and since September 1, 2013, the Company no longer leases space from KARD. At December 31, 2017 and June 30, 2017, rent payable to KARD or pays rent to KARD.of approximately $15,000 and $21,000, respectively, were included in accrued expenses.

 

In September 2013, the Company signed a lease extension agreement with Cummings Properties for the Company’scompany’s offices and laboratories at 100 Cummings Center, Suite 151-B Beverly, MA 01915. The lease is for a term of five years from October 1, 2013 to September 30, 2018 and requires monthly payments of approximately $18,000. CellceutixThe Company had taken over the space occupied by KARD. In addition, Innovative Medical Research Inc., (“Innovative Medical”) a company owned by LeoMr. Ehrlich and Dr. Krishna Menon, officers and directors of Cellecutix,the Company, has co-signed the lease and rents approximately 200 square feet of office space, the space previously used by Cellceutixthe Company and pays Cellceutixthe Company $900 per month, the same amount Cellceutixthe Company previously paid KARD. Innovative Medical paid total rent of approximately $3,000 and $6,000 to Cellceutixthe Company for both of the three months and six months ended December 31, 20162017 and 2015, respectively,2016 and the rental payment was offset with the accrued rent owed to KARD.

 

At December 31, 2016 and June 30, 2016, rent payable to KARD of approximately $26,000 and $32,000, respectively, were included in accrued rent – related party.

Clinical Studies

 

The Company previously engaged KARD to conduct specified pre-clinical studies. The Company did not have an exclusive arrangement with KARD. All work performed by KARD needed prior approval by the executive officers of the Company, and the Company retained all intellectual property resulting from the services by KARD. The Company now has its own research study capabilities and no longer uses KARD. As ofAt December 31, 20162017 and June 30, 2016,2017, the accrued research and development expenses payable to KARD was approximately $1,486,000 and this amount was included in accounts payable.

 

10.Other related party transactions are disclosed in Note 9 below.

Note 9. Convertible Note Payable - Related Party

 

During the year ended June 30, 2010, Mr. Ehrlich loaned the Company a total of approximately $973,000. A condition for this note was that the Ehrlich Promissory Note A and Ehrlich Promissory Note B be replaced with a new note, Ehrlich Promissory Note CC. The Ehrlich Promissory Note C is an unsecured demand note that bears 9% simple interest per annum and is convertible into the Company’s Class A common stock at $0.50 per share. The note requires that the interest rate on the amounts due on Ehrlich Promissory Notes A and B be changed retroactively, beginning October 1, 2009, to 9%. On April 1, 2011, the Company amended the Ehrlich Promissory Note C and agreed to retroactively convert accrued interest of approximately $97,000 through December 31, 2010 into additional principal. During the year ended June 30, 2011, Mr. Ehrlich loaned the Company an additional approximate(approximate) $997,000 which brought the total balance of the demand note to approximately $2,002,000. During the year ended June 30, 2012, Mr. Ehrlich loaned the Company an additional $20,000 which brought the balance of thethis demand note to approximately $2,022,000.

13
Table of Contents

 

On May 8, 2012, the Company did not have the ability to repay the Ehrlich Promissory Note C loan and agreed to change the interest rate on the outstanding balance of principal and interest of approximately $2,248,000, as of March 31, 2012, from 9% simple interest to 10% simple interest, and the Company issued 2,000,000 Equity Incentive Options exercisable at $0.51 per share equal to 110% of the closing bid price of $0.46 per share on May 7, 2012. The optionsOptions are valid for ten (10) years from the date of issuance.

 

As ofAt December 31, 20162017 and June 30, 2016,2017, approximately $112,000$22,000 and $40,000,$17,000, respectively, wasis the accrued as interest expensepayable on this note.

 

As ofAt December 31, 20162017 and June 30, 2016,2017, principal balancesbalance of thethis demand note was approximately $2,022,000.

 

13
Table of Contents

11.Note 10. Equity Incentive Plans, Stock-Based Compensation, Exercise of Options and Warrants Outstanding

 

Equity Incentive Plans

2009 Stock Option Plan

On April 5, 2009 the Board of Directors of the Company adopted the 2009 Stock Option Plan (“the 2009 Plan”). The 2009 Plan permits the grant of 2,000,000 shares of both Incentive Stock Options (“ISOs”), intended to qualify under section 422 of the Code, and Non-Qualified Stock Options.

2010Current Equity Incentive Plan

Under the 2010 Equity Incentive Plan (the "2010 Plan") adopted by the Board of Directors in December 2010, the total number of shares of common stock reserved and available for issuance under the 2010 Plan is 45,000,000 shares. Shares of common stock under the 2010 Plan may consist, in whole or in part, of authorized and unissued shares or treasury shares. The term of each stock option shall be fixed as provided, however, an ISO may be granted only within the ten-year period commencing from the effective date of the 2010 Plan and may only be exercised within ten years of the date of grant (or five years in the case of an ISO granted to an optionee who, at the time of grant, owns common stock possessing more than 10% of the total combined voting power of all classes of voting stock of the Company).

 

2016 Equity Incentive Plan

 

On June 30, 2016, the Board of Directors adopted the Cellceutix CorporationCompany’s 2016 Equity Incentive Plan (the "2016 Plan"“2016 Plan”). The 2016 Plan became effective upon adoption by the Board of Directors on June 30, 2016.

 

Up to 20,000,000 shares of the Company'sCompany’s Class A common stock may be issued under the 2016 Plan (subject to adjustment as described in the 2016 Plan); provided that (1) no Outside Director (as defined in the 2016 Plan) may be granted awards covering more than 250,000 shares of common stock in any year and (2) no participant shall be granted, during any one year period, options to purchase common stock and stock appreciation rights with respect to more than 4,000,000 shares of common stock in the aggregate or any other awards with respect to more than 2,500,000 shares of common stock in the aggregate. The 2016 Plan permits the grant of ISOs, non-qualified stock options, stock appreciation rights, restricted awards, performance share awards and performance compensation awards to employees, directors, and consultants of the Company and its affiliates.

 

In connection with adoption of the 2016 Plan, the Board of Directors also approved forms of Incentive Stock Option Agreement for Employees, Non-qualified Stock Option Agreement for Employees, Non-qualified Stock Option Agreement for Non-Employee Directors, Restricted Stock Award Agreement for Employees and Restricted Stock Award Agreement for Non-Employee Directors that will be utilized by the Company to grant options and restricted shares under the 2016 Plan.

 

Stock Options Issued and Outstanding

The following table summarizes all stock option activity under the aboveCompany’s equity incentive plans:

 

 

 

Number of
Options

 

 

Weighted

Average
Exercise
Price

 

 

Weighted Average
Remaining Contractual Life (Years)

 

 

Aggregate
Intrinsic Value

 

Outstanding at June 30, 2016

 

 

40,444,728

 

 

$0.22

 

 

 

4.58

 

 

$48,185,911

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

368,779

 

 

 

1.31

 

 

 

9.55

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited/expired

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Outstanding at December 31, 2016

 

 

40,813,507

 

 

$0.23

 

 

 

4.13

 

 

$39,336,598

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at December 31, 2016

 

 

39,769,611

 

 

$0.20

 

 

 

4.00

 

 

$39,334,409

 

 

 

Number of Options

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Aggregate Intrinsic Value

 

Outstanding at June 30, 2017

 

 

40,655,245

 

 

$0.22

 

 

 

3.61

 

 

$31,662,730

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Granted

 

 

795,826

 

 

 

0.71

 

 

 

9.67

 

 

 

 

 

Forfeited/expired

 

 

(172,500)

 

 

3.26

 

 

 

 

 

 

 

 

 

Outstanding at December 31, 2017

 

 

41,278,571

 

 

 

0.22

 

 

 

3.24

 

 

$21,696,800

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at December 31, 2017

 

 

40,356,641

 

 

 

0.21

 

 

 

3.10

 

 

$21,696,800

 

 

 
14
Table of Contents

 

The fair value of options granted for the six months ended December 31, 20162017 and 20152016 was estimated on the date of grant using the Black Scholes model that uses assumptions noted in the following table.

 

 

Six Months Ended

 

 

December 31,

 

 

Six months ended

December 31,

 

2016

 

 

2015

 

 

2017

 

2016

 

Expected term (in years)

 

3 - 10

 

 

3

 

 

10

 

3 - 10

 

Expected stock price volatility

 

57.63% to 111.62%

 

56.52% to 65.76%

 

 

106.01%

 

57.63% to 111.62%

 

Risk-free interest rate

 

0.71% to 1.73%

 

1.04% to 1.16%

 

 

2.15%

 

0.71% to 1.73%

 

Expected dividend yield

 

0

 

0

 

 

0

 

0

 

Stock-Based Compensation

 

The Company recognized approximately $347,000$1,400,000 and $432,000$690,000 of total stock-based compensation costs related to stock and stock options awards for the three months ended December 31, 2016 and 2015, respectively. The Company recognized approximately $690,000 and $530,000 of total stock-based compensation costs related to stock and stock optionsequity grant awards for the six months ended December 31, 2017 and 2016, respectively. The $1,400,000 of stock- based compensation expense for the six months ended December 31, 2017 included approximately $516,000 of stock options expense and 2015, respectively.$884,000 of restricted stock awards.

 

For the six months ended December 31, 2017

On September 1, 2017, the Company agreed to grant to Dr. Arthur Bertolino, the President and Chief Medical Officer of the Company, under the 2016 Plan (i) 1,066,667 shares of restricted stock and (ii) a ten-year option to purchase 617,839 shares of the Company’s Class A common stock at an exercise price of $0.705 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) 50% upon the first anniversary of the effective date and the remaining 50% upon the second anniversary of the effective date; (2) shares of the Company’s common stock close above $3.00 per share (as may be adjusted for any stock splits or similar actions); (3) the commencement of trading of shares of the Company’s common stock on a national securities exchange; or (4) upon a change in control of the Company. The $690,0001,066,667 shares were valued at approximately $752,000 and the 617,839 stock options valued at approximately $399,000. Both shares and options will be amortized over 2 years to September 1, 2019 unless the probability of the other above vesting requirements occurring are met at an earlier date. At December 31, 2017, the Company determined that it was not probable that these accelerated vesting provisions would occur earlier than the scheduled vesting date. During the three months and six months ended December 31, 2017, the Company recorded approximately $144,000 and $192,000 of total stock-based compensation, respectively. The $144,000 of stock-based compensation expense for the three months ended December 31, 2017 included approximately $50,000 of stock option expense and $94,000 of stock awards. The $192,000 of stock-based compensation expense for the six months ended December 31, 20162017 included approximately $272,000$67,000 of stock optionsoption expense and $418,000$125,000 of stock awards (see Note 12).

For the six months ended December 31, 2016awards.

 

On February 16, 2016,September 1, 2017, the Company issued 119,424agreed to grant to Ms. Jane Harness, the Vice President, Clinical Sciences and Portfolio Management of the Company under the 2016 Plan (i) 58,394 shares of restricted stock optionsand (ii) a ten-year option to purchase 172,987 shares of the Company’s Class A common stock par value $0.0001 per share to two consultants for services, valued at approximately $55,000, based on the closing bid price as quoted on the OTC on February 16, 2016 at $1.15 per share. These options were issued with an exercise price of $1.105. One third vested immediately,$0.705 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) one third vested in six months (August 11, 2016),upon the first anniversary of the effective date, one third upon the second anniversary of the effective date, and the balanceremaining one third upon the third anniversary of the effective date; or (2) upon a change in control of the Company. The 58,394 shares were valued at approximately $41,000 and the 172,987 stock options valued at approximately $112,000. Both shares and options will be vested on February 11, 2017, and will be valid for a period of three years. These options have piggyback registration rights. The Company recorded approximately $5,000 and $14,000 of stock options expense duringamortized over 3 years to September 1, 2020 unless the other vesting requirements are met sooner. During the three months and six months ended December 31, 2016,2017, the Company recorded approximately $13,000 and $17,000 of total stock-based compensation, respectively. The $13,000 of stock-based compensation expense for the three months ended December 31, 2017 included approximately $10,000 of stock option expense and $3,000 of stock awards. The $17,000 of stock-based compensation expense for the six months ended December 31, 2017 included approximately $13,000 of stock option expense and $4,000 of stock awards.

15
Table of Contents

 

On April 6, 2016,September 1, 2017, the Company issued 25,000 shares and 25,000 stockagreed to grant to Anne Ponugoti, under the 2016 Plan, ten-year options to purchase 5,000 shares of the Company’s common stock par value $0.0001 per share to a consultant for service. The stock options were valued at approximately $14,000, based on the closing bid price as quoted on the OTC on April 6, 2016 at $1.61 per share. These options were issued with an exercise price of $1.77 and$0.705 per share, which shall vest on April 30, 2017, withupon the earliest to occur of the following: (1) one third upon the first anniversary of the effective date, one-third upon the second anniversary of the effective date, and the remaining one-third upon the third anniversary of the effective date; or (2) upon a three year option term. Thesechange in control of the Company. The 5,000 stock options have piggyback registration rights. The Company recordedvalued at approximately $3,000 and $6,000 of stock option expenses forit will be amortized over 3 years to September 1, 2020 unless the other vesting requirements are met sooner. During the three months and six months ended December 31, 2017, the Company recorded approximately $300 and $400 of stock option expense for this option grant.

On January 9, 2017, the Company and Ms. Ponugoti entered into an executive employment agreement as the Company’s Associate Director, Clinical Sciences, effective on February 1, 2017. Pursuant to the employment agreement, the Company issued 10,000 shares of restricted stock and options to purchase 30,000 shares of common stock under the 2016 Plan. During the three months and six months ended December 31, 2017, the Company recorded approximately $4,000 and $7,000 of total stock-based compensation, respectively. The value$4,000 of stock-based compensation expense for the three months ended December 31, 2017 included approximately $3,000 of stock option expense and $1,000 of stock awards. The $7,000 of stock-based compensation expense for the six months ended December 31, 2017 included approximately $5,000 of stock option expense and $2,000 of stock awards.

Purchase of Treasury Stock - cash paid to Federal and State Taxing Authorities arising from the withholding of common shares from an officer’s vested restricted stock grant issuance and issuance of Treasury Stock and the reversal of outstanding stock subscription receivable

On September 1, 2017, 19,465 shares of the Company’s restricted stock vested to Ms. Harness according to Ms. Harness’s employment agreement. The total taxable compensation to Ms. Harness for the 19,465 vested shares was $14,000, which is priced at the closing stock price on September 1, 2017 at $0.705 a share.

The Company issued 12,409 common shares (net share issuance amount), which is approximately 64% of the total vested common share amount of 19,465 common shares due to be issued to Ms. Harness. The remaining 7,056 shares of common stock were withheld from Ms. Harness for the payment of payroll taxes to the Federal and State taxing authorities and these 25,000 shares withheld are being reported by the Company as treasury stock, at $1.61 percost, on the Company’s accompanying balance sheets.

On December 22, 2017, 533,334 shares of the Company’s restricted stock vested to Dr. Arthur P. Bertolino according to Dr. Arthur P. Bertolino’s employment agreement. The total taxable compensation to Dr. Arthur P. Bertolino for the 533,334 vested shares was $373,334, which is priced at the closing stock price on December 21, 2017 at $0.7 a share.

The Company issued 295,286 common shares (net share issuance amount), which is approximately 55% of the total vested common share amount of 533,334 common shares due to be issued to Dr. Arthur P. Bertolino. The remaining 238,048 shares of common stock were withheld from Dr. Arthur P. Bertolino for the payment of payroll taxes to the Federal and State taxing authorities and these shares withheld are being reported by the Company as treasury stock, at cost, on the Company’s accompanying balance sheets.

In addition, the Company reversed an outstanding stock subscription receivable of $26,000 for 60,000 shares of common stock and recorded this amount as the cost of treasury stock.

There were 567,184 shares and 262,080 shares of treasury stock outstanding at December 31, 2017 and June 30, 2017, respectively, purchased at a total cumulative cost of $417,000 and $220,000 at December 31, 2017 and June 30, 2017, respectively.

Restricted Stock Awards Outstanding

The following summarizes our restricted stock activity for our restricted stock issuances:

 

 

 

 

 

Weighted

 

 

 

 

 

 

Average

 

 

 

 

 

 

Grant

 

 

 

Number of

 

 

Date Fair

 

 

 

Shares

 

 

Value

 

 

 

 

 

 

 

 

Total awards outstanding at June 30, 2017

 

 

601,728

 

 

$1.39

 

Total shares granted

 

 

1,125,061

 

 

 

0.71

 

Total shares vested

 

 

(552,799)

 

 

1.40

 

Total shares forfeited

 

 

 

 

 

 

 

 

Total unvested shares outstanding at December 31, 2017

 

 

1,173,990

 

 

$0.75

 

16
Table of Contents

Scheduled vesting for outstanding restricted stock awards at December 31, 2017 is as follows:

 

 

Year Ending June 30,

 

 

 

2018

 

 

2019

 

 

2020

 

 

2021

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Scheduled vesting

 

 

3,333

 

 

 

575,596

 

 

 

575,597

 

 

 

19,464

 

 

 

1,173,990

 

As of December 31, 2017, there was approximately $40,250.$0.7 million of net unrecognized compensation cost related to unvested restricted stock-based compensation arrangements. This compensation is recognized on a straight-line basis resulting in approximately $0.3 million of compensation expected to be expensed over the next twelve months, and the total unrecognized stock-based compensation expense having a weighted average recognition period of 1.72 years.

For the six months ended December 31, 2016

Issuances of Common Stock and Stock Options – Pursuant to New Employment Agreements

 

On June 27, 2016, the Company and Dr. Bertolino entered into an executive employment agreement as our President and Chief Medical Officer of the Company, effective on June 27, 2016. Commencing on June 27, 2016 the Company agreed to pay Dr. Bertolino an annual salary of $440,000. In addition,and the Company agreed to grant to Dr. Bertolino under the Cellceutix CorporationCompany’s 2016 Equity Incentive Plan (i) 1,066,667 shares of restricted stock and (ii) a ten-year option to purchase 617,839 shares of the Company'sCompany’s Class A common stock at an exercise price of $1.39 per share. Both shares and options shall vest upon the earliest to occur of the following: (1) 50% upon the first anniversary of the effective date, and the remaining 50% upon the second anniversary of the effective date (2) completion of both a Phase 2b psoriasis study and a Phase 2 oral mucositis study; (3) the Company’s common stock closes above $3.00 per share (as may be adjusted for any stock splits or similar actions); (4) the commencement of trading of the Company’s common stock on a national securities exchange (e.g. Nasdaq or the NYSE); or (5) upon a Change in Control of the Company (as defined in the employment agreement) of the Company. The Company could not conclude that it was probable that these awards will fully vest until the second anniversary of the effective date, because such events listed above are outside the Company’s control. The Company will evaluate the probability of these events occurring for each reporting period.. The 1,066,667 shares were valued at approximately $1.5 million, which will be amortized over two years to June 27, 2018. The 617,839 stock options were valued at approximately $800,000 and will be exercisable for 10 years at an exercise price of $1.39 per share. They will be amortized over 2 years to June 27, 2018 or sooner if the Company determines that it is probable that one of the events listed above will occur. During the three months and six months ended December 31, 2016,2017, the Company recorded approximately $289,000$845,000 and $578,000$1,134,000 of total stock-based compensation, respectively. The $289,000$845,000 of stock basedstock-based compensation expense for the three months ended December 31, 20162017 included approximately $101,000$295,000 of stock option expense and $188,000$550,000 of stock awards. The $578,000$1,134,000 of stock basedstock-based compensation expense for the six months ended December 31, 20162017 included approximately $202,000$396,000 of stock option expense and $376,000$738,000 of stock awards.

 
15
Table of Contents

TheIn December, 2017 and October, 2017, respectively, the Company may award Dr. Arthur P. Bertolino an annual bonus atwas able to conclude both the sole discretionPhase 2b psoriasis study and a Phase 2 oral mucositis study; therefore the remaining 50% of the Board of Directors ofshares and options vested to Dr. Bertolino, and all remaining shares and options granted on June 27, 2016 were fully amortized and expensed during the Company. The Company may accelerate the amortization of the $1.1 million stock-based compensation expense if there are conditions which will accelerate the vesting, as mentioned above. Atthree-month period ended December 31, 2016, it was determined by management that is was not probable that these accelerated vesting conditions would occur and therefore there was no accrual recorded for the contingent acceleration of this stock-based compensation expense.2017.

 

On July 18, 2016, the Company issued 7,500 stock options to purchase shares of the Company’s common stock to a consultant for serviceservices rendered, exercisable for 3 years at $1.38 per share of common stock. The value of these 7,500 options was approximately $4,000. During the three months and six months ended December 31,September 30, 2016, the Company recorded approximately $0 and $4,000 of total stock option expense respectively.for this option grant.

 

On September 1, 2016, the Company and JaneMs. Harness entered into an executive employment agreement as the Company’s VP, Clinical Sciences and ProjectPortfolio Management, effective on September 1, 2016. Commencing on September 1, 2016, the Company agreed to pay Ms. Harness an annual salary of $250,000. In addition, the Company agreed to grant to Ms. Harness, under the Cellceutix Corporation 2016 Equity Incentive Plan (i) 58,394 shares of restricted stock, which shall vest upon the earliest to occur of the following: (1) one third (33 1/3 %) upon the first anniversary of the effective date, one third (33 1/3 %)one-third upon the second anniversary of the effective date, and the remaining one third (33 1/3 %)one-third upon the third anniversary of the effective date; or (2) upon a Change in Control (as defined in the employment agreement) of the Company. Ten-yearCompany, and (ii) ten-year options to purchase 172,987 shares of the Company’s common stock were also granted at an exercise price of $1.37 per share, which shall vest upon the earliest to occur of the following: (1) one third (33 1/3 %)one-third upon the first anniversary of the effective date, and the remaining balance vesting monthly in equal portions over the following 24 months; and (2) upon a Change in Control (as defined in the employment agreement) of the Company. The 58,394 shares were valued at approximately $80,000, which will be amortized over three years to September 1, 2019. The 172,987 stock options were valued at approximately $220,000 and will be exercisable for 10 years at an exercise price of $1.26$1.37 per share. They will be amortized over 3 years to September 1, 2019. During the three months and six months ended December 31, 2016,2017, the Company recorded approximately $25,000 and $33,000$50,000 of total stock-based compensation, respectively. The $25,000 of stock basedstock-based compensation expense for the three months ended December 31, 20162017 included approximately $18,000 of stock option expense and $7,000 of stock awards. The $33,000$50,000 of stock basedstock-based compensation expense for the six months ended December 31, 20162017 included approximately $24,000$36,000 of stock option expense and $9,000$14,000 of stock awards.

17
Table of Contents

 

On September 15, 2016, the Company and LaVonneDr. Lang entered into an executive employment agreement as the Company’s VP, Regulatory Affairs, effective on September 15, 2016. Commencing on September 15, 2016, the Company agreed to pay Dr. Lang an annual salary of $250,000. In addition, the Company agreed to grant to Dr. Lang under the Cellceutix Corporation 2016 Equity Incentive Plan (i) 63,492 shares of restricted stock, which shall vest upon the earliest to occur of the following: (1) one third (33 1/3 %)one-third upon the first anniversary of the effective date, one third (33 1/3 %) upon the second anniversary of the effective date, and the remaining one third (33 1/3 %)one-third upon the third anniversary of the effective date; or (2) upon a Change in Control (as defined in the employment agreement) of the Company. Ten-yearCompany, and (ii) ten-year options to purchase 188,262 shares of the Company’s common stock were also granted at an exercise price of $1.26 per share, which shall vest upon the earliest to occur of the following: (1) one third (33 1/3 %)one-third upon the first anniversary of the effective date, and the remaining balance vesting monthly in equal portions over the following 24 months; and (2) upon a Change in Control (as defined in the employment agreement) of the Company. The 63,492 shares were valued at approximately $80,000, which will be amortized over three years to September 15, 2019. The 188,263188,262 stock options were valued at approximately $220,000 and will be exercisable for 10 years at an exercise price of $1.26 per share. They will be amortized over 3 years to September 15, 2019. During the three months and six months ended December 31, 2017 and 2016, the Company recorded approximately $25,000$0 and $29,000$4,000 of total stock-based compensation, respectively. The $25,000 of stock based compensation expense for these equity grants, respectively. There was no stock-based compensation expense for Dr. Lang since she resigned on March 17, 2017 and the three months ended December 31, 201663,492 restricted shares and the 188,262 stock options were forfeited. The $4,000 included approximately $18,000$3,000 of stock option expense and $7,000 of stock awards. The $29,000 of stock based compensation expense$1,000 for the six months ended December 31, 2016 included approximately $21,000 of stock option expense and $8,000 of stock awards.

 

For the six months ended December 31, 2015

On July 10, 2015, the Company issued 7,028 shares and 50,000 options to a consultant for his one year contract, which options are exercisable for 3 years at $2.49 per share of common stock. The total value of these 50,000 options was approximately $60,000 and we recognized approximately $60,000 of stock based compensation costs that was charged to Research and Development expense as of December 31, 2015. The assumptions we used in the Black Scholes option-pricing model were disclosed as above.

16
Table of Contents

Stock Warrants

For the six months ended December 31, 2016

During the six months ended December 31, 2016, there were no warrants issued or exercised.

The following table summarizes stock warrants:

 

 

Warrants

 

 

Weighted Average Exercise Price

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Aggregate Intrinsic Value

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at June 30, 2016

 

 

25,000

 

 

$1.79

 

 

 

0.56

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Extended

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

Expired

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

Outstanding at December 31, 2016

 

 

25,000

 

 

$1.79

 

 

 

0.06

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable at December 31, 2016

 

 

25,000

 

 

$1.79

 

 

 

0.06

 

 

$-

 

12. Equity Transactions

Issuance of Common Stock for Cash

$30 million Class A Common Stock Purchase Agreement with Aspire Capital Fund, LLC

On March 30, 2015, the Company entered into a common stock purchase agreement (the "Purchase Agreement") with Aspire Capital, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company's common stock over the 36-month term of the Purchase Agreement. In consideration for entering into the Purchase Agreement, the Company issued to Aspire Capital 160,000 shares of its Class A common stock as a commitment fee. The commitment fee of approximately $499,000 will be amortized as the funding is received. The amortized amount of $48,000 and $44,000 were recorded to additional paid-in capital during the six months ended December 31, 2016 and 2015. The unamortized portion is carried on the balance sheet as deferred offering costs and was $310,000 and $358,000 at December 31, 2016 and June 30, 2016, respectively. During the period from March 30, 2015 to December 31, 2016, the Company had completed sales to Aspire totaling 8.2 million shares of common stock generating gross proceeds of approximately $11 million.

Concurrently with entering into the Purchase Agreement, the Company also entered into a registration rights agreement with Aspire Capital, in which the Company agreed to file one or more registration statements, as permissible and necessary to register, under the Securities Act of 1933, as amended, the sale of the shares of the Company's common stock that have been and may be issued to Aspire Capital under the Purchase Agreement. The Company has filed with the Securities and Exchange Commission a prospectus supplement, dated March 31, 2015, to the Company's prospectus filed as part of the Company's effective $75 million shelf registration statement on Form S-3, File No. 333-199725, registering all of the shares of common stock that have been or may be offered and sold to Aspire Capital from time to time.

During the six months ended December 31, 2016 and 2015, the Company had completed sales to Aspire totaling 2.4 million shares and 1.5 million shares of common stock generating gross proceeds of approximately $2.9 million and $2.6 million, respectively.

17
Table of Contents

Issuance of Common Stock by Exercise of Common Stock Options

For the six months ended December 31, 2016

During the six months ended December 31, 2016, the Company has no issuance of common stock by exercise of common stock options.

For the six months ended December 31, 2015

During the six months ended December 31, 2015, the Company recorded subscription receivable of $25,400 for the exercise of 60,000 Common Stock options at $0.42 per share.

Issuance of Common Stock to Consultants Forfor Services

For the six months ended December 31, 2016

 

On July 18, 2016, the Company issued 7,500 shares to a consultant for service rendered. The value of these 7,500 shares at $1.38 per share was approximately $10,000.

 

On August 1, 2016, the Company issued 11,720 restricted shares to a consultant for service.service rendered. The value of these 11,720 shares at $1.28 per share was approximately $15,000.

 

Exercise of options

During the three months and six months ended December 31, 2017 and 2016, there were no stock options exercised.

Note 11. Equity Transactions

For the six months ended December 31, 2015

On July 10, 2015, the Company issued 7,028 shares of restricted Class A common shares to a consultant for services rendered. The shares were granted and vested on July 10, 2015. The value of these 7,028 shares at $2.49 per share was approximately $17,500.

Issuances of Common Stock and Stock Options – Pursuant to Employment Agreements2017

 

For$30 million Class A Common Stock Purchase Agreement with Aspire Capital

On September 6, 2017, the Company entered into a common stock purchase agreement with Aspire Capital, which replaced the prior 2015 $30 million Aspire Capital stock purchase agreement and provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Stock Purchase Agreement. The Company issued 300,000 shares of its Class A common stock to Aspire Capital as a commitment fee. The commitment fee of approximately $215,000 is amortized pro-rata as the funding is received. The amortized amount of $31,000 was recorded to additional paid-in capital for the six months ended December 31, 20162017. The unamortized portion is carried on the balance sheet as deferred offering costs and was $183,000 at December 31, 2017. The Company registered the resale of all shares that Aspire Capital will purchase under this common stock purchase agreement. To the extent Aspire Capital purchases shares under this Purchase Agreement and subsequently sells those shares purchased, the other holders of shares of our Class A common stock may experience dilution, which may be substantial. In addition, the sale of a substantial number of shares of our Class A common stock by Aspire Capital, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we might otherwise wish to effect sales.

 

OnDuring the period from September 1, 2016,6, 2017 to December 31, 2017, the Company and Jane Harness entered into an executive employmentgenerated proceeds of approximately $4.4 million under the new 2017 agreement aswith Aspire Capital from the Company’s VP, Clinical Sciences and Project Management, effective on September 1, 2016. Pursuant to the employment agreement, the Company issued 58,394sale of approximately 6.6 million shares of restricted stock and options to purchase 172,987 sharesits common stock. As of common stock to Ms. HarnessDecember 31, 2017, the available balance under the Cellceutix Corporation 2016 Equity Incentive Plan. See Note 11 for additional information concerning the restricted stock and stock options granted to Ms. Harness.

On September 15, 2016, the Company and LaVonne Lang entered into an executive employmentnew equity line agreement as the Company’s VP, Regulatory Affairs, effective on September 15, 2016. Pursuant to the employment agreement, the Company issued 63,492 shares of restricted stock and options to purchase 188,263 shares of common stock to Dr. Lang under the Cellceutix Corporation 2016 Equity Incentive Plan. See Note 11 for additional information concerning the restricted stock and stock options granted to Dr. Lang.was approximately $25.6 million.

The following summarizes our restricted stock activity for the above restricted stock issuances:

 

 

 

 

 

Weighted

 

 

 

 

 

 

Average

 

 

 

 

 

 

Grant

 

 

 

Number of

 

 

Date Fair

 

 

 

Shares

 

 

Value

 

 

 

 

 

 

 

 

Total awards outstanding at June 30, 2016

 

 

1,066,667

 

 

$1.40

 

Total shares granted

 

 

121,886

 

 

 

1.31

 

Total shares outstanding at December 31, 2016

 

 

1,188,553

 

 

$1.39

 

 

 
18
Table of Contents

 

Scheduled vesting for outstanding restrictedOn March 30, 2015, the Company entered into its prior common stock at December 31, 2016 is as follows:

 

 

Year Ending June 30,

 

 

 

2017

 

 

2018

 

 

2019

 

 

2020

 

 

Total

 

Scheduled vesting—restricted stock

 

 

533,333

 

 

 

573,963

 

 

 

40,629

 

 

 

40,628

 

 

 

1,188,533

 

Aspurchase agreement with Aspire Capital, which provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of December 31, 2016, there was $1.3 million of net unrecognized compensation cost related to unvested restricted stock-based compensation arrangements. This compensation is recognized on a straight line basis resulting in approximately $0.8$30.0 million of the compensation expectedCompany’s common stock over the 36-month term of the Purchase Agreement. In consideration for entering into this stock purchase agreement, the Company issued to be expensed inAspire Capital 160,000 shares of its Class A common stock as a commitment fee. The commitment fee of approximately $499,000 was amortized as the next twelvefunding was received. The unamortized portion of deferred offering costs from this stock purchase agreement of $227,000 was recorded to additional paid-in capital during the six months andended December 31, 2017, since the total unrecognized compensation hasCompany entered into a weighted average recognitionnew $30 million common stock purchase agreement with Aspire Capital, to replace this prior $30 million 2015 Aspire Capital agreement, on September 6, 2017. During the period from July 1, 2017 to September 5, 2017, the Company generated proceeds of 1.62 years.approximately $2.1 million under this 2015 agreement with Aspire Capital, from the sale of approximately 2.6 million shares of its common stock.

 

13.Note 12. Subsequent Events

 

Equity Transactions

From January 4, 20171, 2018 to January 20, 2017,February 7, 2018, the Company has generated additional proceeds of approximately $455,000$0.6 million under the Common Stock Purchase Agreement with Aspire Capital from the sale 400,000of approximately 0.9 million shares of its common stock.

 

On February 1, 2018, 3,333 shares of the Company’s restricted stock vested to Ms. Anne Ponugoti according to Ms. Ponugoti’s employment agreement. The total taxable compensation to Ms. Ponugoti for the 3,333 vested shares was $2,433, which is priced at the closing stock price on January 31, 2018 at $0.73 a share. The Company issued 2,645 common shares (net share issuance amount), which is approximately 79% of the total vested common share amount of 3,333 common shares due to be issued to Ms. Ponugoti. The remaining 688 shares of common stock were withheld from Ms. Ponugoti for the payment of payroll taxes to the Federal and State taxing authorities.

On February 5, 2018, the Board of Directors approved the retirement of 567,872 shares of its common stock in treasury, which shares are issued but are not outstanding. These shares included the 688 shares withheld from Ms. Ponugoti, as a result, all treasury shares of the Company were retired.

 
19
Table of Contents

 

ITEM 2. MANAGEMENT'SMANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and plan of operations should be read in conjunction with the financial statements and the notes to those statements included in this Form 10-Q. This discussion includes forward-looking statements that involve risk and uncertainties. You should review our important note about forward-looking statements preceding the financial statements.statements in Item 1 of this Part I. As a result of many factors, such as those set forth under “Risk Factors” in this Form 10-Q and in our Annual Report on Form 10-K, actual results may differ materially from those anticipated in these forward-looking statements.

 

Management’s Plan of Operation

 

Overview

 

CellceutixInnovation Pharmaceuticals Inc. is a clinical stage biopharmaceutical company developing innovative therapies withfor inflammatory diseases, oncology, dermatology, and antimicrobialanti-infectives applications. CellceutixThe Company owns the rights to numerous drug compounds, including Kevetrin (thioureidobutyronitrile), our lead anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis; and Brilacidin, our lead drug in a new class of compounds called defensin-mimetics.defensin-mimetics; and Kevetrin (thioureidobutyronitrile), our lead anti-cancer compound.

Effective June 5, 2017, the Company changed its name from Cellceutix Corporation to Innovation Pharmaceuticals Inc.

 

The Company devotes most of its efforts and resources on its compounds already in clinical trials. These trials are evaluating our drug candidates: Kevetrin for the treatment of cancers,trials: Prurisol for the treatment of psoriasis, Kevetrin for the treatment of ovarian cancer, and Brilacidin for treatments of skin infections, ulcerative proctitis (Inflammatory Bowel Disease) and prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative proctitis.cancer. We anticipate using our expertise to manage and perform what we believe are the most critical aspects of the product development process which include: (i) design and oversight of clinical trials; (ii) development and execution of strategies for the protection and maintenance of intellectual property rights; and (iii) interactions with regulatory authorities domestically and internationally. We expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials.

 

Clinical Development Programs

Compound

Target/Indication

Clinical Status

Prurisol

Psoriasis

Phase 2b (Completed)

Brilacidin

*ABSSSI

Phase 2 (Completed)

Oral Mucositis

Phase 2 (Completed; Fast Track)

Inflammatory Bowel Disease

Phase 2 (Proof of Concept) Study (Completed)

Kevetrin

Ovarian Cancer

Phase 2

________________

*ABSSSI- Acute Bacterial Skin and Skin Structure Infection

20
Table of Contents

Recent Developments

 

At this timeBusiness Development Activities

A key strategic priority for the Company is focusingremains the out-licensing of its researchmid-stage, first-in-class clinical assets to global and/or specialty pharmaceutical companies who have expressed an interest in our pipeline. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties.

Research and development efforts are concentrated on Kevetrin, Prurisol, Brilacidin, and Kevetrin:

·

Prurisol - Prurisol, our lead anti-psoriasis drug candidate, is a small molecule compound acting on the principles of immune modulation and PRINS (Psoriasis susceptibility-related RNA Gene Induced by Stress) reduction that has been found to be effective against psoriasis in animal models, both in induced psoriasis as well as a xenograft model with human psoriatic tissue. It is currently in Phase 2 clinical development with the recently completed study below:

Active Clinical Trials: Phase 2b, Multi-center, Randomized, Double Blind, Parallel Group, Placebo-controlled Trial to Study the Efficacy and Safety of Two Oral Doses of Prurisol Administered Twice Daily for Twelve Weeks to Subjects with Moderate to Severe Chronic Plaque Psoriasis

·

Brilacidin - This lead drug candidate is in a new immunomodulatory class with anti-inflammatory and antibiotic properties called defensin-mimetics. Modeled after Host Defense Proteins (HDPs), the “front-line” of defense in the immune system, it is a small, non-peptidic, synthetic molecule that kills pathogens swiftly and thoroughly. Just as importantly, Brilacidin also functions in a robust immunomodulatory capacity, lessening inflammation and promoting healing. In June 2017, the Company completed an open-label Phase 2 Proof-of-Concept (PoC) trial of Brilacidin for the treatment by daily enema of ulcerative proctitis (UP)/ ulcerative proctosigmoiditis (UPS), two types of Inflammatory Bowel Diseases (IBD). Study results showed significant patient benefit and low systemic absorption. The Company is also studying Brilacidin’s effect on Oral Mucositis (under Fast Track designation) and, in October 2017, announced it had completed the Phase 2 study below:

Active Clinical Trials: Phase 2, Multi-center, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients with Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy

·

Kevetrin - Our lead anti-cancer compound, is a small molecule compound that modulates p53, a protein involved in controlling cell mutations. In the majority of all cancers, regardless of origin, the p53 pathway is mutated, compromising its anti-tumor functions. In particular, most epithelial ovarian cancer patients have high-grade serous cancer, characterized by near universal p53 gene abnormalities. Pre-clinical research has demonstrated Kevetrin’s unique mechanism of action to induce apoptosis, slow tumor progression and reduce tumor volume in many types of cancers, including lung, breast, colon, prostate, squamous cell carcinoma and a leukemia tumor model. The FDA has awarded Orphan Drug designations for Kevetrin for ovarian cancer, retinoblastoma and pancreatic cancer as well as Rare Pediatric Disease designation for Retinoblastoma. It is currently in the Phase 2 clinical development study below:

Active Clinical Trials: A Phase 2 study of Kevetrin (thioureidobutyronitrile) in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

We are a clinical stage company. We have no product sales to date and we will not receive any product revenue until we receive approval from the FDA or equivalent foreign regulatory agencies to begin marketing a lesser extentpharmaceutical product. Developing pharmaceutical products, however, is a lengthy and very expensive process. Assuming we do not encounter any unforeseen safety or efficacy issues during the course of developing our product candidates, we do not expect to complete the development of a product candidate for several years, if ever.

In early 2018, the Company approved steps to focus its efforts on ourclinical trials for its lead drug candidates. Among other anti-bacterialchanges, the salary of Dr. Krishna Menon, the Company’s President of Research, was reduced by 50%, and anti-fungal compounds. the Company anticipates further reductions to staff unrelated to clinical trials.

21
Table of Contents

The Company’s common stock traded under the stock symbol “CTIX” on the OTCQB until the market close of June 8, 2017. As of June 9, 2017, trading on the OTCQB began under the new Innovation Pharmaceuticals name and ticker symbol “IPIX”.

Set forth below is an overview of our research and development efforts on Prurisol, Kevetrin, Prurisol and Brilacidin for the six months ended December 31, 2016during fiscal 2018 and through the date of this Quarterly Report on Form 10-Q:10-Q. We have entered into multiple non-disclosure agreements with large and mid-sized pharmaceutical companies that enable us to continue ongoing discussions regarding potential partnering should the below trial results support such a relationship.

Prurisol

The Company recently completed a randomized, double-blind, parallel-group, placebo-controlled Phase 2b trial of Prurisol for subjects with moderate to severe plaque psoriasis. The treatment group arms are Prurisol 300mg, Placebo, Prurisol 400mg (Ratio 3:3:1) with a treatment duration of twelve weeks.

We are currently awaiting data from the trial. Subject recruitment was slower than projected due to competitive trials. In response, we added additional investigator sites. We completed the trial in December 2017. Our expenditures on Prurisol were approximately $3.3 million and $1.6 million during the six months ended December 31, 2017 and 2016, respectively.

Future expenditures on Prurisol will be determined by the trial results when available.

 

Kevetrin.

The first-in-human clinical trial evaluating the safety and pharmacokinetics of Kevetrin was completed at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. The study enrolled a total of 48 patients, who had failed previous therapies, with various types of advanced solid tumors, including 11 patients with advanced ovarian cancer. A dose-escalation design was used with patients enrolled in 11 cohorts with the maximum dose administered at 750 mg/m2. Kevetrin appeared to be safe and well tolerated, with no dose-limiting toxicities occurring among patients who received even the highest dose of Kevetrin. Cellceutix is currently preparing forCompany has commenced a Phase 2a trial of Kevetrin in treating late-stage ovarian cancer. The clinical protocol was submitted to and approved by the study site’s institutional review board (IRB) and we anticipate start of the study 1Q2017 after submission to the FDA. The main objective of thisthe trial focuses on confirming the modulation by Kevetrin of p53 pathways in tumors, as well as monitoring the response of tumors to the treatment. PresentlyHighly encouraging preliminary positive data from the first patients treated showed direct evidence of molecular pathways modulation in tumors. Modulation of the p53 protein was observed in response to administration of Kevetrin; pathways analyses also pointed to concomitant cell cycle modulation at the level of gene expression. The Company believes that further pathways detail and planned concurrentclinical tumor responses would best be observable with more frequent and potentially higher drug exposure. Thus, the Phase 2aCompany has decided to discontinue further enrollment into the current clinical trial isand consider a similar trial when ongoing efforts result in the development of an oral formulation of Kevetrin for treating cancer. Pharmacokinetic data collected on Kevetrin during the initial Phase 1 clinical trial demonstrates that the compound has a short half-life of approximately two hours. Kevetrin’s short half-life makes it a compelling candidate for an oral drug delivery treatment for the main purpose of allowing simple daily, or multiple-times daily, administrations within or outside the hospital setting. Compared to injectable or intravenous treatments, oral therapy is the preferred drug delivery method of patients. Preliminary laboratory studies are encouraging and support the potential of developing an oral formulation, of Kevetrin, but there are no assurances made or implied that Cellceutixthe Company will be successful in completing development of an oral formulation of Kevetrin.formulation. Toxicology studies for the oral formulation of Kevetrin began January 2017.

 

Cellceutix’sOur expenditures on Kevetrin were approximately $0.2$0.3 million and $0.3 million during the three months and six months ended December 31, 2017 and 2016, respectively.

 

 
2022
Table of Contents

 

PrurisolBrilacidin. The Company completed an initial Phase 2 trial of oral Prurisol for mild to moderate plaque psoriasis. After a detailed analysis, the data showed that the most robust response to Prurisol was in patients with moderate psoriasis in the trial’s highest dosing arm (200mg), with no serious adverse events reported in that arm. Among these patients (with the severest form of psoriasis in study), those having a baseline IGA score of 3 (“moderate”), the primary endpoint was met in 46% (Per Protocol) and 40% (Intent-to-Treat) of patients who received 200 mg of Prurisol per day. These data were derived from analyses of all patients. Benefits were apparent by two weeks and showed further improvement by the end of the study at 12 weeks.

Cellceutix has commenced a randomized, double-blind, parallel-group, placebo-controlled Phase 2b trial of Prurisol for approximately 189 subjects with moderate to severe plaque psoriasis. Daily Prurisol dosage has been increased from 200mg. The treatment group arms are Prurisol 300mg, Placebo, Prurisol 400mg (Ratio 3:3:1) with a treatment duration of 12 weeks.

The Company expects interim analysis top-line results in the second quarter of calendar 2017. Cellceutix’s expenditures on Prurisol were approximately $1.2 million and $1.6 million during the three months and six months ended December 31, 2016, respectively. We expect our expenditures on Prurisol to increase in future reporting periods, depending on the Company’s future financing.

In December 2016 management reviewed Cellceutix’s development of Prurisol (KM133) and determined that no royalties on its sales would be due to outside parties.

 

Topical Brilacidin Clinical Studies (Trials). ABSSSI - In February 2016, Cellceutix submitted a Special Protocol Assessment (SPA) request, along with a final protocol, to the FDA, for a Phase 3 clinical

One trial of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). We received from the FDA comments and considerations for incorporation into our study design. Management has decided to delay its response to FDA due to the low price per share of our common stock and the approximately $30 million costs required for this study which would resultcompleted in significant dilution to our shareholders. Our strategy for now is to achieve success with other trials and attract partnering opportunities with significant down payments and milestone payments which can fund these trials.

Topical Brilacidin- Other trials of Brilacidin remain ongoing, includingOctober 2017 was a double-blind Phase 2 clinical trial of Brilacidin-OM for the treatment of oral mucositis (OM), and another was completed in July 2017, which was an open-label Phase 2 Proof-of-Concept (P-o-C)(PoC) trial of Brilacidin for the treatment of ulcerative proctitis (UP) or ulcerative proctosigmoiditis (UPS)/proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Diseases (IBD).

 

Oral Mucositis (OM): Study - In October 2016, Cellceutix disclosedthe completed randomized, double-blind Phase 2 study of Brilacidin for the prevention and control of OM in patients receiving chemoradiation for treatment of head and neck cancer, interim analysis of patients who received at least 55 Gy cumulative units of radiation showed the use of Brilacidin-OM met its primary endpoint with a clearly reduced incidence of severe OM (SOM) (WHO Grade ≥ 3) compared to placebo. A summary of key secondary endpoints analysis showed that based on Kaplan-Meier curves, Brilacidin-OM oral rinse showed a clear separation from placebo in delaying the onset of SOM—particularly the period from approximately 28-42 days, after the initiation of treatment, during which the incidence of SOM rose strikingly in the placebo group while not in the group being treated with Brilacidin. The delay of onset of SOM data further support the positive primary endpoint findings that showed a clear reduction in the incidence of SOM in patients receiving Brilacidin-OM treatment.

Given that Brilacidin-OM successfully prevented SOM from occurring, as well as delayed its onset, in a substantial number of patients, data comparisons aimed at assessing potential reduction in the duration of SOM were constrained by the fewer number of Brilacidin-OM treated patients that could be included in such analysis. While Brilacidin-OM appeared to decrease the initial duration of SOM (time from the initial WHO Grade ≥ 3 to the first WHO Grade ≤ 2 OM assessment), detailed interpretation of interim results from the this and other duration data comparisons were limited.

UP/UPS study. The ongoingUPS: Study - This completed Phase 22a trial comprises three sequential cohorts, (6 patients per cohort), with progressive dose escalation by cohort—50Cohort A (6 patients) -50 mg, 100Cohort B (6 patients) -100 mg, and Cohort C (5 patients) - 200 mg, respectively. Treatment with Brilacidin by daily enema administration iswas performed for 42 days. AtThe Primary Efficacy Endpoint of Clinical Remission (accounting for Stool Frequency, Rectal Bleeding and Endoscopy Findings subscores) was met by the timemajority of interim data release, fourpatients across the cohorts. Brilacidin was generally well-tolerated. Patient Quality of six patients inLife (as assessed by the lowest dosing cohort (50 mg) completed the study. ComparisonShort Inflammatory Bowel Disease Questionnaire or “SIBDQ”) showed notable improvements. Limited systemic exposure to baseline after six weeks of treatment showed that all four patients completing the study experienced a clinically meaningful response,Brilacidin was demonstrated as measured by the partial or full Modified Mayo Disease Activity Index (MMDAI), without measurable plasma drug levels. More specifically, measurementsBrilacidin concentrations. Further analyses of concentrations of Brilacidindata are ongoing.

We see significant opportunities in plasma showed all levels, across all time points,treating IBD with Brilacidin. Our development programs depending on available financial resources include new formulations (oral and foam type) with potential associated toxicology studies and clinical studies to be below the lower limit of quantification (i.e., <100 ng/mL), which is consistent with limited systemic exposure from administration per rectum by enema. defined.

These data suggest that other inflammatory conditions may, likewise, be treated locally and efficaciously with Brilacidin without significant systemic absorption, better ensuring a safe and well-tolerated therapeutic profile. Given Brilacidin’s low level of systemic exposure, moderate-to-high dosing of the drug by topical application to the skin might also be supported in treating various dermatology disorders and conditions. All six patients for

ABSSSI

In February 2016, the second of three cohorts have been recruitedCompany submitted a Special Protocol Assessment (SPA) request, along with a final protocol, to the study, with the cohort’s completion anticipatedFDA, for late February 2017.

Additional reporting of results from thea Phase 2 P-o-C3 clinical trial of Brilacidin-UP/UPSBrilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). We received comments and considerations from the FDA for incorporation into our study design. Management has decided to delay its response to FDA due to the low price per share of our common stock and the approximate $30 million costs required for this study which would result in significant dilution to our shareholders. Our strategy for now is anticipated over the coming months, as is an interim analysis in the first half of 2017 of the Phase 2 clinical trial of Brilacidin-OM. Cellceutix’sto achieve success with other trials and attract partnering opportunities with significant down-payments and milestone payments which can fund these trials.

Our expenditures on Brilacidin were approximately $0.1$1.2 million and $0.8 million during the three months and six months ended December 31, 2017 and 2016, respectively.

23
Table of Contents

 

Compounds with Activity Against Gram-Negative Bacteria and Fungi

 

We have further reduced costs associated with the licensing of intellectual property for these diseases by returning certain patent portfolios back to the university licensor. Research at Cellceutixthe Company is now focused on supporting our clinical trials. As business conditions warrant, we will determine our financial commitment to the gram-negative bacteria and fungi programs.

 

21
Table of Contents

Critical Accounting Policies and Estimates

 

Management'sManagement’s discussion and analysis of financial condition and results of operations are based upon our accompanying financial statements, which have been prepared in conformity with U.S. generally accepted accounting principles, or U.S. GAAP, and which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe are reasonable under the circumstances. These estimates are the basis for our judgments about the carrying values of assets and liabilities, which in turn may impact our reported revenue and expenses. Our actual results could differ significantly from these estimates under different assumptions or conditions.

 

Please see Note 3 of Part I, Item 1 of this Quarterly Report on Form 10-Q for the summary of significant accounting policies. In addition, please see Part II, Item 7, "Critical“Critical Accounting Policies and Estimates"Estimates” in our Annual Report on Form 10-K for the year ended June 30, 2016.2017. There have been no material changes to our critical accounting policies and estimates since our Annual Report on Form 10-K for the year ended June 30, 2016.2017.

 

Recently Issued Accounting Pronouncements

 

SeePlease see Note 3 to the Financial Statements, Significant Accounting Policies and Recent Accounting Pronouncements, in the accompanying notes to Financial Statements for a discussion of recent accounting pronouncements and their effect, if any, on our financial statements.

 

Results of Operations

 

We expect to incur losses from operations for the next few years. We expect to incur increasing research and development expenses, including expenses related to additional clinical trials for our proprietary programs. We expect that our general and administrative expenses will also increase in the future as we expand our business development, by adding employees, consultants, additional infrastructure and incurring other additional costs. Based upon our expected rate of expenditures over the next 12twelve months and beyond, managementwe will seekneed additional working capital to meet the Company’sour anticipated clinical trial obligations and Company overhead. other working capital requirements.

 

For the three months ended December 31, 20162017 and 20152016

 

Revenue

 

We generated no revenue and incurred operating expenses of $3.3approximately $4.5 million and $3.3 million for the three months ended December 31, 2017 and 2016, and 2015, respectively.

 

Research and Development Expenses for Proprietary Programs

 

Below is a summary of our research and development expenses for our proprietary programs by categories of costs for the three months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

For the three months ended

 

 

 

 

For the three months ended

 

Change

 

 

December 31,

 

2016 vs. 2015

 

 

December 31,

 

2017 Vs. 2016

 

 

2016

 

 

2015

 

 

$

%

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical studies and development research

 

$1,662,000

 

$1,615,000

 

47,000

 

3%

 

$2,341,000

 

$1,662,000

 

679,000

 

41%

Officers' payroll and payroll tax expenses related to R&D department

 

218,000

 

106,000

 

112,000

 

106%

Employees payroll and payroll tax expenses related to R&D department

 

354,000

 

299,000

 

55,000

 

18%

Officers’ payroll and payroll tax expenses related to R&D Department

 

223,000

 

218,000

 

5,000

 

2%

Employees payroll and payroll tax expenses related to R&D Department

 

262,000

 

354,000

 

(92,000)

 

(26)%

Stock-based compensation - officers

 

289,000

 

-

 

289,000

 

-

 

 

989,000

 

289,000

 

700,000

 

242%

Stock-based compensation - employee

 

50,000

 

-

 

50,000

 

-

 

Stock-based compensation - employees

 

42,000

 

50,000

 

(8,000)

 

(16)%

Stock-based compensation - consultants

 

8,000

 

-

 

8,000

 

-

 

 

-

 

8,000

 

(8,000)

 

(100)%

Depreciation and amortization Expenses

 

 

102,000

 

 

 

110,000

 

 

 

(8,000)

 

 

(7)%

 

 

 

 

 

 

 

 

 

Depreciation and amortization expenses

 

 

106,000

 

 

 

102,000

 

 

 

4,000

 

 

 

4%

Total

 

$2,683,000

 

 

$2,130,000

 

 

 

553,000

 

 

 

26%

 

$3,963,000

 

 

$2,683,000

 

 

 

1,280,000

 

 

 

48%

 

 
2224
Table of Contents

 

Research and development expenses for proprietary programs increased during the three months ended December 31, 2016,2017 primarily due to higher spending on our KevetrinBrilacidin program and Prurisol program offset by the final settlement of disputed accounts payable related to Brilacidin program of approximately $600,000.program.

 

Officers'Officers’ payroll will decrease in future periods due to the 50% reduction in salary of one officer, which became effective on January 16, 2018. Clinical studies and development expenses may decrease in future reporting periods depending on the Company’s current and future financial liquidity.

Employees payroll and payroll tax expenses related to R&D department increaseddecreased during the three months ended December 31, 2016 primarily2017 related to fewer employees engaged in preclinical development in September, 2017, which led to the hiring of our President and Chief Medical Officer who joined us on June 27, 2016.decrease in employees’ payroll during the quarter ended December 31, 2017.

 

Employees’ payroll and payroll tax expenses increased primarily related to the hiring of our VP Clinical Services and Project Management.

Stock-basedStock- based compensation - officers increased during the three months ended December 31, 20162017 primarily related to the stock-based compensation given to our new President and Chief Medical Officer who joined uson September 1, 2017 and the vesting milestones for the stocks and options granted to our President and Chief Medical Officer on June 27, 2016.2016 became fully vested and expensed for the completed clinical trials in December, 2017.

 

Stock-based compensation- employee increased during the three months ended December 31, 2016 primarily related to the stock-based compensation given to our new VP Regulatory Affairs and our VP Clinical Services and Project Management who joined us in September, 2016.

Stock-based compensation- consultants increased during the three months ended December 31, 2016 due to amortization of stock awards granted in previous periods. There were no new stock awards during the second quarter of fiscal 2017 and no stock awards in the second quarter of fiscal 2016.

Depreciation and amortization expenses decreased during the three months ended December 31, 20162017 due to less amortization expenses on those patent cost being written off at last fiscal year.the decrease in stock awards granted to employees during the quarter ended December 31, 2017 compared with the same period in 2016.

Stock-based compensation- consultant decreased during the three months ended December 31, 2017 due to no stock awards were granted to consultants during the quarter ended December 31, 2017.

 

Our research and development expenses include costs related to preclinical and clinical trials, outsourced services and consulting, officers'officers’ payroll and related payroll tax expenses, other wages and related payroll tax expenses, stock-based compensation, depreciation and amortization expenses. We manage our proprietary programs based on scientific data and achievement of research plan goals. Our scientists record their time to specific projects when possible; however, many activities occurring simultaneously benefit multiple projects and cannot be readily attributed to a specific project. Accordingly, the accurate assignment of time and costs to a specific project is difficult and may not give a true indication of the actual costs of a particular project. As a result, we do not report costs on an individual program basis.

 

General and Administrative Expenses

 

General and administrative expenses consist mainly of compensation and associated fringe benefits not included in cost of research and development expenses for proprietary programs and include other management, business development, accounting, information technology and administration costs, including patent filing and prosecution, recruiting, consulting and professional services, travel and meals, facilities, depreciation and other office expenses.

 

Below is a summary of our general and administrative expenses for the three months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

Three months ended

 

 

 

 

For the three months ended

 

Change

 

 

December 31

 

2016 vs. 2015 

 

 

December 31,

 

2017 vs. 2016

 

 

2016

 

2015 

 

$

 

 

%

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Insurance and health expense

 

$121,000

 

$128,000

 

(7,000)

 

(5)%

 

$109,000

 

$121,000

 

(12,000)

 

(10)%

Patent expenses

 

-

 

 

 

-

 

-

%

Rent and utility expense

 

69,000

 

64,000

 

5,000

 

8%

 

65,000

 

69,000

 

(4,000)

 

(6)%

Other G&A

 

 

154,000

 

 

 

160,000

 

 

 

(6,000)

 

 

(4)%

 

 

123,000

 

 

 

154,000

 

 

 

(31,000)

 

 

(20)%

Total

 

$344,000

 

 

$352,000

 

 

 

(8,000)

 

 

(2)%

 

$297,000

 

 

$344,000

 

 

 

(47,000)

 

 

(14)%

 

General and administrative expenses decreased during the three months ended December 31, 2017 primarily related to decreases in promotion, advertising and office expenses.

 
2325
Table of Contents

 

Officers' payrollOfficers’ Payroll and payroll tax expensesPayroll Tax Expenses

 

Below is a summary of our Officers'Officers’ payroll and payroll tax expenses for the three months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

 

Three months ended

 

 

 

 

 

 

December 31

 

 

2016 vs. 2015 

 

 

 

2016 

 

 

2015

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Officers' payroll and payroll tax expenses

 

$130,000

 

 

$130,000

 

 

 

-

 

 

 

-

 

 

 

Three months ended

 

 

Change

 

 

 

December 31

 

 

2017 vs. 2016

 

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Officers’ payroll and payroll tax expenses

 

$130,000

 

 

$130,000

 

 

 

-

 

 

 

-

 

 

There was no change in Officers'Officers’ payroll and payroll tax expenses for the Company during the three months ended December 31, 20162017 and 2015.2016. The officers’ payroll and payroll tax expenses represented one officer’s annual payroll and payroll tax expenses and 10% of payroll and payroll tax expenses paid for Mr.Dr. Menon. The Company recorded 90% of annual payroll paid to Mr.Dr. Menon and histhe related payroll tax expenses under Research and Development Expense.

 

Professional feesFees

 

Below is a summary of our Professional fees for the three months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

 

Three months ended

 

 

 

 

 

 

December 31,

 

 

2016 vs. 2015 

 

 

 

2016

 

 

2015

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Audit Fee, legal and professional fees

 

$152,000

 

 

$662,000

 

 

 

(510,000)

 

 

(77)%

 

 

Three months ended

 

 

Change

 

 

 

December 31,

 

 

2017 vs. 2016

 

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Audit, legal and professional fees

 

$78,000

 

 

 

152,000

 

 

 

(74,000)

 

 

(49)%

 

Professional fees decreased during the three months ended December 31, 20162017 primarily related to decrease in stock options paid to a law firm for services, valued at approximately $432,000 on November 5, 2015 (see Note 11 in the accompanying Notes to Condensed Financial Statements).legal fees.

 

Other Income (Expense)

 

Below is a summary of our other income (expense) for the three months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

Three months ended

 

 

 

 

Three months ended

 

Change

 

 

December 31,

 

2016 vs. 2015 

 

 

December 31,

 

2017 vs. 2016

 

 

2016

 

2015

 

$

 

 

%

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Income

 

$1,000

 

$1,000

 

-

 

-

 

 

$-

 

1,000

 

(1,000)

 

(100)%

Interest Expenses

 

 

(50,000)

 

 

(50,000)

 

 

-

 

 

 

-

 

 

(50,000)

 

 

(50,000)

 

 

-

 

 

 

-

%

Other Income (Expense), net

 

$(49,000)

 

$(49,000)

 

 

-

 

 

 

-

 

$(50,000)

 

 

(49,000)

 

 

(1,000)

 

 

(2)%

 

There was slight decrease in interest income from bank deposits and there was no change in Interest Income received from banks and interest expenses paid on the note payable – related party (see note 10 inNote 9 to the accompanying Notesnotes to Condensed Financial Statements)the condensed financial statements).

 

Net Losses

 

We incurred net losses of $3.4$4.5 million and $3.3$3.4 million for the three months ended December 31, 20162017 and 2015,2016, respectively because of the aboveabove-mentioned factors.

 

24
Table of Contents

For the six months ended December 31, 20162017 and 20152016

 

Revenue

 

We generated no revenue and incurred operating expenses of $6.3approximately $9.0 million and $5.8$6.3 million for the six months ended December 31, 2017 and 2016, and 2015, respectively.

26
Table of Contents

 

Research and Development Expenses for Proprietary Programs

 

Below is a summary of our research and development expenses for our proprietary programs by categories of costs for the six months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

For the six months ended

 

 

 

 

For the six months ended

 

Change

 

 

December 31,

 

2016 vs. 2015 

 

 

December 31,

 

2017 Vs. 2016

 

 

2016

 

2015

 

$

 

 

%

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Clinical studies and development research

 

$3,009,000

 

$2,837,000

 

172,000

 

6%

 

$5,124,000

 

3,009,000

 

2,115,000

 

70%

Officers' payroll and payroll tax expenses related to R&D department

 

453,000

 

212,000

 

241,000

 

114%

Employees payroll and payroll tax expenses related to R&D department

 

609,000

 

604,000

 

5,000

 

1%

Officers’ payroll and payroll tax expenses related to R&D Department

 

441,000

 

453,000

 

(12,000)

 

(3)%

Employees payroll and payroll tax expenses related to R&D Department

 

592,000

 

609,000

 

(17,000)

 

(3)%

Stock-based compensation - officers

 

578,000

 

20,000

 

558,000

 

2790%

 

1,326,000

 

578,000

 

748,000

 

129%

Stock-based compensation - employee

 

63,000

 

-

 

63,000

 

-

 

Stock-based compensation - employees

 

74,000

 

63,000

 

11,000

 

17%

Stock-based compensation - consultants

 

50,000

 

78,000

 

(28,000)

 

(36)%

 

-

 

50,000

 

(50,000)

 

(100)%

Depreciation and amortization expenses

 

 

198,000

 

 

 

210,000

 

 

 

(12,000)

 

 

(6)%

 

 

211,000

 

 

 

198,000

 

 

 

13,000

 

 

 

7%

 

 

 

 

 

 

 

 

 

Total

 

$4,960,000

 

 

$3,961,000

 

 

 

999,000

 

 

 

25%

 

$7,768,000

 

 

 

4,960,000

 

 

 

2,808,000

 

 

 

57%

 

Research and development expenses for proprietary programs increased during the six months ended December 31, 20162017 primarily due to higher spending on our KevetrinBrilacidin program and Prurisol program offset by the final settlement of disputed accounts payable related to Brilacidin program of approximately $600,000.program.

 

Officers'Officers’ payroll will decrease in future periods due to the 50% reduction in salary of one officer, which became effective on January 16, 2018. Clinical studies and development expenses may decrease in future reporting periods depending on the Company’s current and future financial liquidity.

Employees payroll and payroll tax expenses related to R&D department increaseddecreased during the six months ended December 31, 2016 primarily2017 related to the hiring of our President and Chief Medical Officer who joined us on June 27, 2016.

Employees’ payroll and payroll tax expenses increased primarily related todecrease in employees during the hiring of our VP Clinical Services and Project Management.six months ended December 31, 2017.

 

Stock-based compensation - officers increased during the six months ended December 31, 20162017 primarily related to the stock-based compensation given to our President and Chief Medical Officer on September 1, 2017 and the stocks and options granted to our new President and Chief Medical Officer who joined us on June 27, 2016.2016 that became fully vested and expensed due to the completed clinical trial milestones in December, 2017.

 

Stock-based compensation- employee increased during the six months ended December 31, 2016 primarily related2017 due to the stock-based compensation givenincrease in stock awards to our new VP Regulatory Affairs and our VP Clinical Services and Project Management who joined usemployees during the six months ended December 31, 2017 compared with the same period in September, 2016.

 

Stock-based compensation- consultants decreased during the six months ended December 31, 20162017 due to granting lessfewer stock awards to consultants in the first quarter of fiscal 2017 compared with the first quarter of fiscal 2016.

Depreciation and amortization expenses decreased during the threesix months ended December 31, 2016 due to less amortization expenses on those patent cost being written off at last fiscal year.2017.

 

Our research and development expenses include costs related to preclinical and clinical trials, outsourced services and consulting, officers'officers’ payroll and related payroll tax expenses, other wages and related payroll tax expenses, stock-based compensation, depreciation and amortization expenses. We manage our proprietary programs based on scientific data and achievement of research plan goals. Our scientists record their time to specific projects when possible; however, many activities occurring simultaneously benefit multiple projects and cannot be readily attributed to a specific project. Accordingly, the accurate assignment of time and costs to a specific project is difficult and may not give a true indication of the actual costs of a particular project. As a result, we do not report costs on an individual program basis.

 

25
Table of Contents

General and Administrative Expenses

 

General and administrative expenses consist mainly of compensation and associated fringe benefits not included in cost of research and development expenses for proprietary programs and include other management, business development, accounting, information technology and administration costs, including patent filing and prosecution, recruiting, consulting and professional services, travel and meals, facilities, depreciation and other office expenses.

 
27
Table of Contents

Below is a summary of our general and administrative expenses for the six months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

Six months ended

 

 

 

 

For the six months ended

 

Change

 

 

December 31

 

2016 vs. 2015

 

 

December 31,

 

2017 vs. 2016

 

 

2016

 

2015

 

$

 

 

%

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Insurance and health expense

 

$258,000

 

$249,000

 

9,000

 

4%

 

$236,000

 

258,000

 

(22,000)

 

(9)%

Patent expenses

 

-

 

2,000

 

(2,000)

 

(100)%

Rent and utility expense

 

130,000

 

132,000

 

(2,000)

 

(2)%

 

127,000

 

130,000

 

(3,000)

 

(2)%

Other G&A

 

 

318,000

 

 

 

310,000

 

 

 

8,000

 

 

 

3%

 

 

231,000

 

 

 

316,000

 

 

 

(85,000)

 

 

(27)%

Total

 

$706,000

 

 

$691,000

 

 

 

15,000

 

 

 

2%

 

$594,000

 

 

 

706,000

 

 

 

(112,000)

 

 

(16)%

 

Officers' payrollGeneral and payroll taxadministrative expenses decreased during the six months ended December 31, 2017 primarily related to decreases in promotion, advertising and office expenses.

Officers’ Payroll and Payroll Tax Expenses

 

Below is a summary of our Officers'Officers’ payroll and payroll tax expenses for the six months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

 

Six months ended

 

 

 

 

 

 

December 31

 

 

2016 vs. 2015

 

 

 

2016

 

 

2015

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Officers' payroll and payroll tax expenses

 

$260,000

 

 

$260,000

 

 

 

-

 

 

 

-

 

 

 

Six months ended

 

 

Change

 

 

 

December 31

 

 

2017 vs. 2016

 

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Officers’ payroll and payroll tax expenses

 

$260,000

 

 

 

260,000

 

 

 

-

 

 

 

-

%

 

There was no change in Officers'Officers’ payroll and payroll tax expenses for the Company during the six months ended December 31, 20162017 and 2015.2016. The officers’ payroll and payroll tax expenses represented one officer’s annual payroll and payroll tax expenses and 10% of payroll and payroll tax expenses paid for Mr.Dr. Menon. The Company recorded 90% of annual payroll paid to Mr.Dr. Menon and histhe related payroll tax expenses under Research and Development Expense.

 

Professional feesFees

 

Below is a summary of our Professional fees for the six months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

 

Six months ended

 

 

 

 

 

 

December 31,

 

 

2016 vs. 2015

 

 

 

2016

 

 

2015

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Audit Fee, legal and professional fees

 

$361,000

 

 

$889,000

 

 

 

(528,000)

 

 

(59)%

 

 

Six months ended

 

 

Change

 

 

 

December 31,

 

 

2017 vs. 2016

 

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Audit, legal and professional fees

 

$330,000

 

 

 

361,000

 

 

 

(31,000)

 

 

(9)%

 

Professional fees decreased during the six months ended December 31, 20162017 primarily related to decrease in stock options paid to a law firm for services, valued at approximately $432,000 on November 5, 2015 (see Note 11 in the accompanying Notes to Condensed Financial Statements).legal fees.

 

 
2628
Table of Contents

 

Other Income (Expense)

 

Below is a summary of our other income (expense) for the six months ended December 31, 20162017 and 2015,2016, respectively (rounded to nearest thousand):

 

 

Six months ended

 

 

 

 

Six months ended

 

Change

 

 

December 31,

 

2016 vs. 2015

 

 

December 31,

 

2017 vs. 2016

 

 

2016

 

2015

 

$

 

 

%

 

 

2017

 

 

2016

 

 

$

 

 

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest Income

 

$2,000

 

$2,000

 

-

 

-

 

 

$1,000

 

2,000

 

(1,000)

 

(50)%

Interest Expenses

 

 

(101,000)

 

 

(101,000)

 

 

-

 

 

 

-

 

 

 

(101,000)

 

 

(101,000)

 

 

-

 

 

 

-

%

Other Income (Expense), net

 

$(99,000)

 

$(99,000)

 

 

-

 

 

 

-

 

 

$(100,000)

 

 

(99,000)

 

 

(1,000)

 

 

(1)%

 

There was slight decrease in interest income from bank deposits and there was no change in Interest Income received from banks and interest expenses paid on the note payable – related party (see note 10 inNote 9 to the accompanying Notesnotes to Condensed Financial Statements)the condensed financial statements).

 

Net Losses

 

We incurred net losses of $6.4$9.1 million and $5.9$6.4 million for the six months ended December 31, 20162017 and 2015,2016, respectively because of the aboveabove-mentioned factors.

 

Liquidity and Capital Resources

 

Projected Future Working Capital Requirements - Next 12Twelve Months

 

As of December 31, 2016,2017, we had approximately $3.9$3.2 million in cash and $19 million remaining available for stock sales under the terms of the purchase agreement with Aspire Capital, compared to $6.3$4.1 million of cash as of June 30, 2016.2017. We anticipate that future budget expenditures will be approximately $19$12.2 million overfor the next 12twelve months, including approximately $15$8.2 million for clinical trials.

Alternatively, if we decide to pursue a more aggressive plan with our clinical trials, weactivities, supportive research, and drug product development. We will require additional sources of equity capital during the fiscal year ended June 30, 2017,2018 in order to meet our working capital requirements for our planned clinical trials.requirements. This assessment is based on current estimates and assumptions regarding our clinical development programs and business needs. Actual working capital requirements could differ materially from this above working capital projection.

On September 6, 2017, the Company entered into a $30 million common stock purchase agreement with Aspire Capital which replaced the prior $30 million Aspire Capital stock purchase agreement and provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Purchase Agreement. During the period from September 6, 2017 to December 31, 2017, the Company has generated proceeds of approximately $4.4 million under this agreement with Aspire Capital from the sale of approximately 6.6 million shares of its common stock. As of December 31, 2017, the available balance is approximately $25.6 million. Our ability to continue to fund our research and development activities and corporate overhead expenses and continue as a going concern has been and continues to be dependent on this stock purchase agreement.

 

Our ability to successfully raise sufficient funds through the sale of equity securities, when needed, is subject to many risks and uncertainties and even if we are successful, future equity issuances would result in dilution to our existing stockholders. Our risk factors are described under the heading "Risk Factors"“Risk Factors” in Part I, Item 1A and elsewhere in our Annual Report on Form 10-K we filed with the SEC on September 11, 2017 and in other reports we file with the SEC.reports.

 

IfWe have been successful at raising capital in the past but there can be no assurance that additional capital will be available on terms acceptable to us or in amounts sufficient to meet our needs. In the event that we are unable to generate enough workingraise sufficient capital from our current financing agreement with Aspire Capital when needed or secure additional sources of funding itfrom others, we may be necessaryrequired to significantly reduce our current rate of spending through reductions in staff and delaying, scaling back or stopping certain research and development programs, including the more costly Phase 2 clinical trials and potential future Phase 3 clinical trials on our wholly-owned development programs, as these programsclinical trials progress into a later stage development.of development or severely curtail our operations or otherwise impede our ongoing business efforts, or we could be forced to cease operations altogether. Insufficient liquidity may also require us to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to us and our stockholders than we would otherwise choose in order to obtain up-front license fees needed to fund operations. These liquidity events could prevent us from successfully executing our current operating plan.

 

$75 Million Shelf Registration Statement

 

The Company has an effective shelf registration statement on Form S-3, registering the sale of up to $75 million of the Company’s securities. The Company filed the Form S-3 with the Securities and Exchange Commission a prospectus supplement, dated March 31, 2015,SEC on September 11, 2017, which included registering up tothe shares underlying the 2017 $30 million of our common stock that have been or may be offered and sold to Aspire Capital from time to time, leaving $45 million available under the Company’s effective shelf registration statement.stock purchase agreement.

 

 
2729
Table of Contents

 

Aspire Capital Agreement and Other Equity Issuances

On March 30, 2015, the Company entered into a new common stock purchase agreement (the “March 2015 Agreement”) with Aspire Capital which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company's common stock over the 36-month term of the March 2015 Agreement.

During the period from March 30, 2015 to December 31, 2016, the Company had completed sales to Aspire totaling 8.2 million shares of common stock generating gross proceeds of approximately $11 million relating to this $30 million purchase agreement. The Company has $19 million remaining available for stock sales under the terms of the purchase agreement with Aspire Capital. Other Equity Issuances are disclosed in Note 12 in the accompanying Notes to Condensed Financial Statements.

Cash Flows

 

The following table provides information regarding our cash position, cash flows and capital expenditures for the six months ended December 31, 20162017 and 20152016 (rounded to nearest thousand):

 

 

Six Months Ended

December 31,

 

% Change

Increase/

 

 

Six Months Ended

December 31,

 

% Change

Increase/

 

 

2016

 

 

2015

 

 

(decrease)

 

 

2017

 

 

2016

 

 

(Decrease)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net cash used in operating activities

 

$(5,250,000)

 

$(4,640,000)

 

13%

 

$(7,177,000)

 

$(5,250,000)

 

37%

Net cash used in investing activities

 

(117,000)

 

(217,000)

 

(46)%

 

(90,000)

 

(117,000)

 

(23)%

Net cash provided by financing activities

 

 

2,916,000

 

 

 

2,630,000

 

 

 

11%

 

 

6,307,000

 

 

 

2,916,000

 

 

 

116%

Net (decrease) increase in cash

 

$(2,451,000)

 

$(2,227,000)

 

 

10%

Net decrease in cash

 

$(960,000)

 

$(2,451,000)

 

 

(61)%

 

Operating activities

 

The increase in net cash used in operating activities of $0.6$1.9 million versus the prior-year six-month period was mainly due to increaseincreases in our losses from operations of $0.5 million.$2.4 million, largely attributable to our increase spending for research and development expenses.

 

Our operating activities used cash of $5.3approximately $7.2 million and $4.6$5.3 million for the six months ended December 31, 2017 and 2016, and 2015, respectively. The use of cash in these periods principally resulted from our losses from operations, asThis increase was adjusted for non-cash charges for stock-based compensation, amortization and depreciation, and changes in our working capital accounts.

 

Investing activities

 

The decrease in net cash used in investing activities of $0.1 million versus the prior-year six-month period was due to a decrease in acquiring patents costs.

During the six months ended December 31, 2017, our investing activities used cash of $0.1 million, consisting of spending on patent costs of $0.1 million.

During the six months ended December 31, 2016, our investing activities used cash of $0.1 million, including the purchases of fixed assets of $0.05 million and the purchases of patents of $0.05 million. During the six months ended December 31, 2015, our investing activities used cash of $0.2 million, including the purchases of patents of $0.2 million.

 

Financing activities

 

The increase in net cash provided by financing activities of $0.3approximately $3.4 million versus the prior-year six-month period was due to an increase in sales of shares of our common stock to Aspire.Aspire Capital.

 

During the six months ended December 31, 2017, we raised approximately $6.5 million in net cash proceeds from the sale of 9.2 million shares of our common stock to Aspire Capital offset by cash paid to taxing authorities arising from the withholding of shares from employees of $172,000. During the six months ended December 31, 2016, we raised approximately $2.9 million in net cash proceeds, including $2.9 million in net proceeds from the sale of 2.4 million shares of our common stock to Aspire.

During the six months ended December 31, 2015, we raised approximately $2.6 million in net cash proceeds, including $2.6 million in net proceeds from the sale of 1.5 million shares of our common stock to Aspire.

28
Table of Contents
Aspire Capital.

 

Requirement for Additional Working Capital

 

The Company plans to incur total expenses of approximately $19$12.2 million overfor the next twelve months, including approximately $15$8.2 million for clinical trials.activities, supportive research, and drug product development. The Company has limited experience with pharmaceutical drug development. As such, the budget estimate may not be accurate. In addition, the actual work to be performed is not known at this time, other than a broad outline, as is normal with any scientific work. As further work is performed, additional work may become necessary or a change in plans or workload may occur. Such changes may have an adverse impact on our estimated budget and on our projected timeline of drug development.

 

The Company will be unable to proceed with its full planned drug development programs, meet its administrative expense requirements, capital costs, andor staffing costs without accessing (as per current management’s budgets) the remainingits financing available with Aspire Capital of approximately $19$25.6 million as of December 31, 2017. Management has put in place this new 2017 equity purchase agreement with Aspire Capital to fund its future clinical trial expenses and overhead expenses over the next twelve months. This purchase agreement provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of the Company’s common stock over the 36-month term of the Purchase Agreement. Management believes, as of the date of this filing or accessing additional sourcesthat the funding amount from Aspire Capital will be available as needed by the Company. Adverse market conditions in the Company’s per share price of its common stock and its trading volume may prevent the Company from funding its working capital underrequirements as needed.

30
Table of Contents

In the Company’s effective shelf registration statement.event that we are unable to generate sufficient cash from our Aspire Capital purchase agreement or raise additional funds from others, we will be required to delay, reduce or severely curtail our operations or otherwise impede our on-going business efforts, which could have a material adverse effect on our future business, operating results, financial condition and long-term prospects. The Company expects to seek to obtain additional funding through business development activities (i.e. licensing and partnerships) and future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available to us.

 

Contractual Obligations

 

Below is a table that presents our contractual obligations and commercial commitments as of December 31, 20162017 (rounded to the nearest thousand)million):

 

 

 

Payments Due by Period

 

 

 

Total

 

 

Less than
One Year

 

 

2
Year

 

 

3-5
Years

 

 

More than
5 Years

 

Lease obligations (1)

 

$380,000

 

 

$109,000

 

 

$217,000

 

 

$54,000

 

 

$-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total (2)

 

$380,000

 

 

$109,000

 

 

$217,000

 

 

$54,000

 

 

$-

 

 

 

Payments Due by Period

 

 

 

Total

 

 

Less than One Year

 

 

2 Year

 

 

3-5 Years

 

 

More than 5 Years

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CRO obligations (1)

 

$2.7

 

 

$2.7

 

 

$-

 

 

$-

 

 

$-

 

Lease obligations (2)

 

$0.2

 

 

$0.1

 

 

$0.1

 

 

$-

 

 

$-

 

Total

 

$2.9

 

 

$2.8

 

 

$0.1

 

 

$-

 

 

$-

 

_____________________________ 

(1)

The Company has contractual minimum commitments to Contract Research Organizations as of December 31, 2017.

(2)

The Company signed a lease extension agreement with Cummings Properties which began on October 1, 2013. The lease is for a term of five years ending on September 30, 2018, and requires monthly payments of approximately $18,000. The Company will receive $900 per month from the sublease of 200 square feet of space to Innovative Medical Research Inc., a company owned by Leo Ehrlich and Dr. Krishna Menon, officers and directors of our Company, which is not included in the table above.

 

Equity Transactions

From January 1, 2018 to February 7, 2018, the Company has generated additional proceeds of approximately $0.6 million under the Common Stock Purchase Agreement with Aspire Capital from the sale of approximately 0.9 million shares of its common stock.

(2)

The Company has no contractual minimum commitments to Contract Research Organizations as of December 31, 2016. Services are billed to Cellceutix, when performed by the vendors.

 

Off-Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements, as defined in Item 303(a)304(a)(4)(ii) of Regulation S-K.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

The Company maintains an investment portfolio in accordance with our investment policy. The primary objectives of our investment policy isare to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. The Company holds investments that are subject to credit risk, but not interest rate risks. The Company does not own derivative financial instruments in our investment portfolio. Accordingly, the Company does not believe there is any material market risk exposure that would require disclosure under this item.

 

 
2931
Table of Contents

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We have established disclosure controls and procedures to ensure that the information required to be disclosed by the Company in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and that such information is accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

 

As of December 31, 2016,2017, management, with the participation of our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act). Based on such evaluation, as of December 31, 2016,2017, the principal executive officer and principal financial officer of the Company have concluded that the Company’s disclosure controls and procedures are effective.

 

Changes in Internal Controls

 

There have been no changes in our internal control over financial reporting during the quarter ended December 31, 2016,2017, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Limitations on Effectiveness of Controls and Procedures

 

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

 

 
3032
Table of Contents

 

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None

 

ITEM 1A. RISK FACTORS

 

Our operations and financial results are subject to various risks and uncertainties, including those described in Part I, Item 1A, "Risk Factors"“Risk Factors” in our Annual Report on Form 10-K for the year ended June 30, 2016,2017, which could adversely affect our business, financial condition, results of operations, cash flows, and the trading price of our common and capital stock. There have been no material changes to our risk factors since our Annual Report on Form 10-K for the year ended June 30, 2016.2017.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES

 

None

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None

 

ITEM 4. MINE SAFETY DISCLOSURES

 

None

 

ITEM 5. OTHER INFORMATION

 

None

 

 
3133
Table of Contents

 

ITEM 6. EXHIBITS

 

(a) Exhibit index

 

 

(1)

The documents set forth below are filed herewith or incorporated herein by reference to the location indicated.

 

EXHIBIT INDEX

 

Exhibit No.

 

Title

 

Method of Filing

31.1

 

President of Research Certifications required under Section 302 of the Sarbanes Oxley Act of 2002

 

Filed herewith

31.2

 

Chief Executive Officer and Chief Financial Officer Certifications required under Section 302 of the Sarbanes Oxley Act of 2002

 

Filed herewith

32.1

 

President of Research Certifications required under Section 906 of the Sarbanes Oxley Act of 2002

 

Furnished herewith

32.2

 

Chief Executive Officer and Chief Financial Officer Certifications required under Section 906 of the Sarbanes Oxley Act of 2002

 

Furnished herewith

101

 

The following materials from the Company’s Quarterly Report on Form 10-Q for the three months and six months ended December 31, 20162017 formatted in Extensible Business Reporting Language (XBRL): (i) the Condensed Statements of Income, (ii) the Condensed Statements of Comprehensive Income, (iii) the Condensed Balance Sheets, (iv) the Condensed Statements of Cash Flows, and (v) related notes

 

Filed herewith


 
3234
Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

CELLCEUTIX CORPORATION

INNOVATION PHARMACEUTICALS INC.

Dated: February 7, 2018

By:

/s/ Leo Ehrlich

Leo Ehrlich

Chief Executive Officer and Chief Financial Officer

(Principal Executive, Accounting and Financial Officer)

 

By:

/s/ Krishna Menon

Krishna Menon

President of Research

Dated: February 9, 2017

 

 

3335